Alset Inc. 10-Q

10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to _________ 001-39732 Commission File Number Alset EHome International Inc. (Exact name of registrant as specified in its charter) NEVADA 83-1079861 State or other jurisdiction of incorporation or organization (I.R.S. Employer Identification No.) 4800 Montgomery Lane, Suite 210, Bethesda, Maryland 20814 (Address of principal executive offices) (Zip Code) 301-971-3940 Registrant’s telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 par value AEI The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ] Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [X] Smaller reporting company [X] Emerging growth company [X] If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ] Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X] As of May 24, 2021, there were 8,511,637 shares of the registrant’s common stock $0.001 par value per share, issued and outstanding. Table of Contents PART I FINANCIAL INFORMATION F-1 Item 1. Consolidated Financial Statements (Unaudited) Consolidated Balance Sheets – March 31, 2021 and December 31, 2020 F-1 Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Three Months Ended March 31, 2021 and 2020 F-2 Consolidated Statements of Stockholders’ Equity – Three Months Ended March 31, 2021 and 2020 F-3 Consolidated Statements of Cash Flows – Three Months Ended March 31, 2021 and 2020 F-4 Notes to Consolidated Financial Statements F-5 – F-33 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 2 Item 3. Quantitative and Qualitative Disclosure About Market Risk 7 Item 4. Controls and Procedures 7 PART II OTHER INFORMATION 7 Item 1. Legal Proceedings 7 Item 1A. Risk Factors 7 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 7 Item 3. Defaults Upon Senior Securities 7 Item 4. Mine Safety Disclosures 7 Item 5. Other Information 8 Item 6. Exhibits 8 SIGNATURES 10 Part I. Financial Information Alset EHome International Inc. and Subsidiaries Consolidated Balance Sheets (Unaudited) March 31, 2021 December 31, 2020 (As Combined) Assets: Current Assets: Cash $ 20,368,692 $ 24,465,923 Restricted Cash 8,636,391 6,769,533 Account Receivables, Net 1,062,278 1,366,194 Other Receivables 687,120 644,576 Note Receivables - Related Parties 669,561 649,569 Prepaid Expenses 2,894,258 1,470,680 Inventory 8,956 90,068 Investment in Securities at Fair Value 52,164,652 49,172,457 Investment in Securities at Cost 99,997 280,516 Deposits 25,528 47,019 Total Current Assets 86,617,433 84,956,535 Real Estate Rental Properties 2,161,680 - Properties under Development 18,104,033 20,505,591 Operating Lease Right-Of-Use Asset 722,507 574,754 Deposit 271,167 249,676 Loan Receivable - Related Parties 840,000 840,000 Property and Equipment, Net 81,169 85,365 Total Assets $ 108,797,989 $ 107,211,921 Liabilities and Stockholders’ Equity: Current Liabilities: Accounts Payable and Accrued Expenses $ 2,388,448 $ 1,670,320 Accrued Interest - Related Parties 41,239 - Deferred Revenue 3,430,893 2,867,226 Builder Deposits 928,565 1,262,336 Operating Lease Liability 51,686 381,412 Notes Payable 238,935 172,706 Notes Payable - Related Parties 14,837,252 2,350,031 Total Current Liabilities 21,917,018 8,704,031 Long-Term Liabilities: Operating Lease Liability 684,875 193,342 Note Payable, Net of Discount 651,034 636,362 Total Liabilities 23,252,927 9,533,735 Stockholders’ Equity: Preferred Stock, $0.001 par value; 5,000,000 shares authorized, none issued and outstanding Common Stock, $0.001 par value; 20,000,000 shares authorized; 8,580,000 and 8,570,000 shares issued and outstanding on March 31, 2021 and December 31, 2020, respectively 8,580 8,570 Additional Paid In Capital 101,799,367 102,339,666 Accumulated Other Comprehensive Income 1,092,609 2,143,338 Accumulated Deficit (51,029,349 ) (44,793,713 ) Total Alset EHome International Stockholders’ Equity 51,871,207 59,697,861 Non-controlling Interests 33,673,855 37,980,325 Total Stockholders’ Equity 85,545,062 97,678,186 Total Liabilities and Stockholders’ Equity $ 108,797,989 $ 107,211,921 See accompanying notes to consolidated unaudited financial statements. F- 1 Alset EHome International Inc. and Subsidiaries Consolidated Statements of Operations and Other Comprehensive Income (Loss ) For the Three Months Ended March 31, 2021 and 2020 (Unaudited) 2021 2020 Revenue (As Combined) Property Sales $ 3,894,131 $ 2,954,389 Biohealth Product Sales 1,712,783 10,782 Total Revenue 5,606,914 2,965,171 Operating Expenses Cost of Sales 3,697,854 2,383,703 General and Administrative 2,312,505 1,001,850 Inventory Written Off - 2,009 Total Operating Expenses 6,010,359 3,387,562 Operating Losses From Operations (403,445 ) (422,391 ) Other Income (Expense) Interest Income 30,632 19,415 Interest Expense (53,582 ) (60,931 ) Foreign Exchange Transaction Gain 1,462,697 2,260,482 Unrealized (Loss) Gain on Securities Investment (9,535,009 ) 458,422 Realized Loss on Securities Investment (258,245 ) - Loss on Investment on Security by Equity Method (24,847 ) - Finance Costs (582,868 ) (4,903 ) Other Income 11,256 5,471 Total Other (Expense) Income, Net (8,949,966 ) 2,677,956 Net (Loss) Income Before Income Taxes (9,353,411 ) 2,255,565 Income Tax (451,337 ) - Net (Loss) Income (9,804,748 ) 2,255,565 Net (Loss) Income Attributable to Non-Controlling Interest (3,569,112 ) 636,703 Net (Loss) Income Attributable to Common Stockholders $ (6,235,636 ) $ 1,618,862 Other Comprehensive Loss, Net Unrealized Loss on Securities Investment (1,987 ) (12,599 ) Foreign Currency Translation Adjustment (1,769,440 ) (1,674,021 ) Comprehensive (Loss) Income (11,576,175 ) 568,945 Comprehensive (Loss) Income Attributable to Non-controlling Interests (4,328,924 ) 53,133 Comprehensive (Loss) Income Attributable to Common Stockholders $ (7,247,251 ) $ 515,812 Net (Loss) Income Per Share - Basic and Diluted $ (0.73 ) $ 0.16 Weighted Average Common Shares Outstanding - Basic and Diluted 8,572,222 10,001,000 See accompanying notes to consolidated unaudited financial statements. F- 2 Alset EHome International Inc. and Subsidiaries Consolidated Statements of Stockholders’ Equity For the Three Months Ended March 31, 2021 (Unaudited) Preferred Stock Common Stock Additional Accumulated Other Total Alset EHome International Non- Total Shares Par Value $0.001 Shares Par Value $0.001 Paid in Capital Comprehensive Income Accumulated Deficit Stockholders’ Equity Controlling Interests Stockholders’ Equity Balance at January 1, 2021 (As Combined) 8,570,000 $ 8,570 $ 102,339,666 $ 2,143,338 $ (44,793,713 ) $ 59,697,861 $ 37,980,325 $ 97,678,186 Issuance of Stock for Services - - 10,000 10 60,890 - - 60,900 - 60,900 Transactions under Common Control - - - - (57,190,499 ) - - (57,190,499 ) - (57,190,499 ) Sale of Vivacitas to Related Party - - - - 2,279,872 - - 2,279,872 - 2,279,872 Purchase Stock of True Partner from Related Party - - - - 3,274,060 - - 3,274,060 - 3,274,060 Beneficial Conversion Feature - - - - 50,770,192 - - 50,770,192 - 50,770,192 Subsidiary’s Issuance of Stock - - - - 46,099 - - 46,099 34,677 80,776 Proceeds from Selling Subsidiary Equity - - - - 142,675 - - 142,675 107,325 250,000 Change in Non-Controlling Interest - - - - 76,412 (39,067 ) - 37,345 (37,345 ) - Change in Unrealized Gain on Investment - - - - - (1,135 ) - (1,135 ) (852 ) (1,987 ) Foreign Currency Translations - - - - - (1,010,527 ) - (1,010,527 ) (758,913 ) (1,769,440 ) Distribution to Non-Controlling Shareholders - - - - - - - - (82,250 ) (82,250 ) Net Loss - - - - - - (6,235,636 ) (6,235,636 ) (3,569,112 ) (9,804,748 ) Balance at March 31, 2021 8,580,000 $ 8,580 $ 101,799,367 $ 1,092,609 $ (51,029,349 ) $ 51,871,207 $ 33,673,855 $ 85,545,062 Alset EHome International Inc. and Subsidiaries Consolidated Statements of Stockholders’ Equity For the Three Months Ended March 31, 2020 (Unaudited) Preferred Stock Common Stock Additional Accumulated Other Total Alset EHome International Non- Total Shares Par Value $0.001 Shares Par Value $0.001 Paid in Capital Comprehensive Income Accumulated Deficit Stockholders’ Equity Controlling Interests Stockholders’ Equity Balance at January 1, 2020 (As Combined) 10,001,000 $ 10,001 $ 57,924,795 $ 1,458,289 $ (41,973,373 ) $ 17,419,712 $ 7,024,783 $ 24,444,495 Subsidiary’s Issuance of Stock - - - - 1,929,765 - - 1,929,765 302,726 2,232,491 Proceeds from Selling Subsidiary Equity - - - - 3,270 - - 3,270 1,730 5,000 Change in Unrealized Loss on Investment - - - - - (8,240 ) - (8,240 ) (4,359 ) (12,599 ) Foreign Currency Translations - - - - - (1,094,810 ) - (1,094,810 ) (579,211 ) (1,674,021 ) Distribution to Non-Controlling Shareholders - - - - - - - (197,400 ) (197,400 ) Net Income - - - - - - 1,626,062 1,626,062 629,502 2,255,564 Balance at March 31, 2020 (As Combined) 10,001,000 $ 10,001 $ 59,857,830 $ 355,239 $ (40,347,311 ) $ 19,875,760 $ 7,177,771 $ 27,053,530 See accompanying notes to consolidated unaudited financial statements. F- 3 Alset EHome International Inc. and Subsidiaries Consolidated Statements of Cash Flows For the Three Months Ended March 31, 2021 and 2020 (Unaudited) 2021 2020 (As Combined) Cash Flows from Operating Activities Net Income (Loss) from Operations $ (9,804,748 ) $ 2,255,565 Adjustments to Reconcile Net Income (Loss) to Net Cash Used in Operating Activities: Depreciation 7,873 5,942 Amortization of Right -Of - Use Asset 81,013 70,671 Amortization of Debt Discount 553,961 - Shared-based Compensation 134,192 - Foreign Exchange Transaction Gain (1,462,697 ) (2,296,128 ) Unrealized Loss (Gain) on Securities Investment 9,548,251 (458,426 ) Loss on Equity Method Investment 24,847 - Changes in Operating Assets and Liabilities Real Estate 441,764 15,952 Account Receivables 203,816 342,575 Prepaid Expense (1,458,620 ) (40,805 ) Trading Securities (2,452,754 ) Inventory 77,709 (20,590 ) Accounts Payable and Accrued Expenses 596,355 231,421 Accrued Interest - Related Parties 41,239 19,634 Deferred Revenue 563,667 50,270 Operating Lease Liability (66,954 ) (73,668 ) Builder Deposits (333,771 ) (285,010 ) Net Cash Used in Operating Activities (3,304,857 ) (182,597 ) Cash Flows from Investing Activities Purchase of Fixed Assets (3,767 ) (1,386 ) Proceeds from Global Opportunity Fund Liquidation - 303,349 Purchase of Investment Securities (108,208 ) - Sales of Investment Securities to Related Party 2,480,000 - Promissory Note to Related Party (15,489 ) (200,000 ) Net Cash Provided by Investing Activities 2,352,536 101,963 Cash Flows from Financing Activities Proceeds from Exercise of Subsidiary Warrants 7,484 - Proceeds from Sale of Subsidiary Shares 250,000 2,210,491 Borrowing from PPP Loan 68,502 - Distribution to Non-controlling Interest Shareholders (82,250 ) (197,400 ) Net Proceeds from (Repayment to) Notes Payable - Related Parties (1,200,000 ) 17,501 Net Cash (Used in) Provided by Financing Activities (956,264 ) 2,030,592 Net Increase in Cash and Restricted Cash (1,908,585 ) 1,949,958 Effects of Foreign Exchange Rates on Cash (321,788 ) (39,411 ) Cash and Restricted Cash - Beginning of Year 31,235,456 8,039,433 Cash and Restricted Cash- End of Period $ 29,005,083 $ 9,949,980 Supplementary Cash Flow Information Cash Paid for Interest $ 6,627 $ 4,181 Cash Paid for Taxes $ 451,410 $ - Supplemental Disclosure of Non-Cash Investing and Financing Activities Unrealized Gain on Investment $ (1,987 ) $ - Initial Recognition of ROU / Lease Liability $ 256,928 $ - Acquiring True Partner Stock $ 10,003,689 $ - Sales of Investment in Vivacitas to Related Party $ 2,279,872 $ - Transactions under Common Control $ 57,190,499 $ - Beneficial Conversion Feature $ (50,770,192 ) $ - See accompanying notes to consolidated unaudited financial statements. F- 4 1. NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations Alset EHome International Inc. (the “Company” or “AEI”), formerly known as HF Enterprises Inc., was incorporated in the State of Delaware on March 7, 2018 and 1,000 shares of common stock was issued to Chan Heng Fai, the founder, Chairman and Chief Executive Officer of the Company. AEI is a diversified holding company principally engaged in property development, digital transformation technology and biohealth businesses with operations in the United States, Singapore, Hong Kong, Australia and South Korea. The Company manages its principal businesses primarily through its subsidiary, Alset International Limited (“Alset International”, f.k.a. Singapore eDevelopment Limited), a company publicly traded on the Singapore Stock Exchange. The Company has four operating segments based on the products and services offered. These include our three principal businesses – property development, digital transformation technology and biohealth – as well as a fourth category consisting of certain other business activities. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and following the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. These interim financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company’s financial information. These interim results are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or any other interim periods or for any other future years. These unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Form 10-K for the year ended December 31, 2020 filed on April 14, 2021. The consolidated financial statements include all accounts of the Company and its majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than 50% of the voting common stock and controls operations. All intercompany transactions and balances among consolidated subsidiaries have been eliminated. The Company’s consolidated financial statements include the financial position, results of operations and cash flows of the following entities as of March 31, 2021 and December 31, 2020, as follows: Attributable interest as of, Name of subsidiary consolidated under AEI State or other jurisdiction of incorporation or organization March 31, 2021 December 31, 2020 % % Hengfai International Pte. Ltd Singapore 100 100 Hengfai Business Development Pte. Ltd Singapore 100 100 Heng Fai Enterprises Pte. Ltd. Singapore - 100 Global eHealth Limited Hong Kong 100 100 Alset International Inc. (f.k.a. Singapore eDevelopment Limited) Singapore 57.1 57.1 Singapore Construction & Development Pte. Ltd. Singapore 57.1 57.1 Art eStudio Pte. Ltd. Singapore 29.1 * 29.1 * Singapore Construction Pte. Ltd. Singapore 57.1 57.1 Global BioMedical Pte. Ltd. Singapore 57.1 57.1 Alset Innovation Pte. Ltd. (f.k.a. SeD Investment Pte. Ltd.) Singapore 57.1 57.1 Health Wealth Happiness Pte. Ltd. Singapore 57.1 57.1 SeD Capital Pte. Ltd. Singapore 57.1 57.1 LiquidValue Asset Management Pte. Ltd. (f.k.a. HengFai Asset Management Pte. Ltd.) Singapore 64.8 46.9 * SeD Home Limited Hong Kong 57.1 57.1 SeD Management Pte. Ltd. (f.k.a. SeD Reits Management Pte. Ltd.) Singapore 57.1 57.1 Global TechFund of Fund Pte. Ltd. Singapore 57.1 57.1 Singapore eChainLogistic Pte. Ltd. Singapore 57.1 57.1 BMI Capital Partners International Limited. Hong Kong 57.1 57.1 SeD Perth Pty. Ltd. Australia 57.1 57.1 SeD Intelligent Home Inc. (f.k.a SeD Home International, Inc.) United States of America 57.1 57.1 F- 5 LiquidValue Development Inc. (f.k.a. SeD Intelligent Home Inc.) United States of America 57.1 57.1 Alset EHome Inc. (f.k.a. Alset iHome Inc., SeD Home & REITs Inc. and SeD Home, Inc.) United States of America 57.1 57.1 SeD USA, LLC United States of America 57.1 57.1 150 Black Oak GP, Inc. United States of America 57.1 57.1 SeD Development USA Inc. United States of America 57.1 57.1 150 CCM Black Oak, Ltd. United States of America 57.1 57.1 SeD Texas Home, LLC United States of America 57.1 57.1 SeD Ballenger, LLC United States of America 57.1 57.1 SeD Maryland Development, LLC United States of America 47.7 * 47.8 * SeD Development Management, LLC United States of America 48.5 * 48.6 * SeD Builder, LLC United States of America 57.1 57.1 GigWorld Inc. (f.k.a. HotApp Blockchain Inc.) United States of America 56.9 57.0 HotApp BlockChain Pte. Ltd. (f.k.a. HotApps International Pte. Ltd.) Singapore 56.9 57.0 HotApp International Limited Hong Kong 56.9 57.0 HWH International, Inc. United States of America 57.1 57.1 Health Wealth & Happiness Inc. United States of America 57.1 57.1 HWH Multi-Strategy Investment, Inc. United States of America 57.1 57.1 SeDHome Rental Inc United States of America 57.1 57.1 SeD REIT Inc. United States of America 57.1 57.1 Gig Stablecoin Inc. (f.k.a. Crypto Exchange Inc.) United States of America 56.9 57.0 HWH World Inc. United States of America 56.9 57.0 HWH World Pte. Ltd. Singapore 56.9 57.0 UBeauty Limited Hong Kong 57.1 57.1 WeBeauty Korea Inc Korea 57.1 57.1 HWH World Limited Hong Kong 57.1 57.1 HWH World Inc. Korea 57.1 57.1 Alset BioHealth Pte. Ltd. Singapore 57.1 57.1 Alset Energy Pte. Ltd. Singapore 57.1 57.1 Alset Payment Inc. United States of America 57.1 57.1 Alset World Pte. Ltd. Singapore 57.1 57.1 BioHealth Water Inc. United States of America 57.1 57.1 Impact BioHealth Pte. Ltd. Singapore 57.1 57.1 American Home REIT Inc. United States of America 64.8 46.9 * Alset Solar Inc. United States of America 45.7 * 45.7 * HWH KOR Inc. United States of America 57.1 57.1 Open House Inc. United States of America 57.1 57.1 Open Rental Inc. United States of America 57.1 57.1 Hapi Cafe Inc. (Nevada) United States of America 57.1 57.1 Global Solar REIT Inc. United States of America 57.1 57.1 OpenBiz Inc. United States of America 57.1 57.1 Hapi Cafe Inc. (Texas) United States of America 100 100 HWH (S) Pte. Ltd. Singapore 57.1 - American Pacific Bancorp Inc. United States of America 86.44 - Hengfeng Finance Limited Hong Kong 86.44 - Decentralize Finance Inc. United States of America 86.44 - True Partner International Limited Hong Kong 100 - LiquidValue Development Pte. Ltd. Singapore 100 - LiquidValue Development Limited. Hong Kong 100 - *Although the Company indirectly holds percentage of shares of these entities less than 50%, the subsidiaries of the Company directly hold more than 50% of shares of these entities, and therefore, they are still consolidated into the Company. F- 6 Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include, but are not limited to, allowance for doubtful accounts, valuation of real estate assets, allocation of development costs and capitalized interest to sold lots, fair value of the investments, the valuation allowance of deferred taxes, and contingencies. Actual results could differ from those estimates. In our property development business, land acquisition costs are allocated to each lot based on the area method, the size of the lot compared to the total size of all lots in the project. Development costs and capitalized interest are allocated to lots sold based on the total expected development and interest costs of the completed project and allocating a percentage of those costs based on the selling price of the sold lot compared to the expected sales values of all lots in the project. If allocation of development costs and capitalized interest based on the projection and relative expected sales value is impracticable, those costs could also be allocated based on area method, the size of the lot compared to the total size of all lots in the project. Transactions between Entities under Common Control On March 12, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with Chan Heng Fai, the founder, Chairman and Chief Executive Officer of the Company, for four proposed transactions, consisting of (i) purchase of certain warrants (the “Warrants”) to purchase 1,500,000,000 shares of Alset International Limited (“Alset International”), which was valued at $28,363,966; (ii) purchase of all of the issued and outstanding stock of LiquidValue Development Pte Ltd. (“LVD”), which was valued at $173,395; (iii) purchase of 62,122,908 ordinary shares in True Partner Capital Holding Limited (HKG: 8657) (“True Partner”), which was valued at $6,729,629; and (iv) purchase of 4,775,523 shares of the common stock of American Pacific Bancorp Inc. (“APB”), which was valued at $28,653,138. The total amount of above four transactions was $63,920,129, payable on the Closing Date by the Company, in the convertible promissory notes (“Alset CPNs”), which, subject to the terms and conditions of the Alset CPNs and the Company’s shareholder approval, shall be convertible into shares of the Company’s common stock (“AEI Common Stock”), par value $0.001 per share, at the conversion price of AEI’s Stock Market Price. AEI’s Stock Market Price shall be $5.59 per share, equivalent to the average of the five closing per share prices of AEI’s Common Stock preceding January 4, 2021 as quoted by Bloomberg L.P. The above four acquisitions from Chan Heng Fai are transactions between entities under common control. The common control transactions resulted in the following basis of accounting for the financial reporting periods: ● The acquisitions of the Warrants and True Partner stock were accounted for prospectively as of March 12, 2021 and they did not represent a change in reporting entity. ● The acquisitions of LVD and APB were under common control and is consolidated in accordance with ASC 850-50. The consolidated financial statements were retrospectively adjusted for the acquisition of LVD and APB, and the operating results of LVD and APB as of January 1, 2020 for comparative purposes. AEI stock price was $10.03 on March 12, 2021, the commitment date. The Beneficial Conversion Feature (“BCF”) intrinsic value was $50,770,192 for the four convertible promissory notes and was recorded as debt discount of convertible notes after these transactions. The debt discount attributable to the BCF is amortized over period from issuance to the date that the debt becomes convertible using the effective interest method. If the debt is converted, the discounted is amortized to finance cost in full immediately. As of March 31, 2021, the promissory notes net of debt discount were $13,695,853 and accrued interest was $41,239. During the three months ended on March 31, 2021, the amortized debt discount recorded as finance cost was $545,916. F- 7 Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents. Cash and cash equivalents include cash on hand and at the bank and short-term deposits with financial institutions that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in values. There were no cash equivalents as of March 31, 2021 and December 31, 2020. Restricted Cash As a condition to the loan agreement with the Manufacturers and Traders Trust Company (“M&T Bank”), the Company is required to maintain a minimum of $2,600,000 in an interest-bearing account maintained by the lender as additional security for the loans. The fund is required to remain as collateral for the loan until the loan is paid off in full and the loan agreement is terminated. The Company also has an escrow account with M&T Bank to deposit a portion of cash proceeds from lot sales. The fund in the escrow account is specifically used for the payment of the loan from M&T Bank. The fund is required to remain in the escrow account for the loan payment until the loan agreement terminates. As of March 31, 2021 and December 31, 2020, the total balance of these two accounts was $8,099,097 and $5,729,067, respectively. As a condition to the loan agreement with National Australian Bank Limited in conjunction with the Perth project, an Australian real estate development project, the Company is required to maintain Australian Dollar 50,000, in a non-interest-bearing account. As of March 31, 2021 and December 31, 2020, the account balance was $38,043 and $38,550, respectively. These funds will remain as collateral for the loans until paid in full. The Company puts money into brokerage accounts specifically for equity investment. As of March 31, 2021 and December 31, 2020, the cash balance in these brokerage accounts was $499,251 and $1,001,916, respectively. Account Receivables and Allowance for Doubtful Accounts Account receivables is stated at amounts due from buyers, contractors, and all third parties, net of an allowance for doubtful accounts. As of March 31, 2021 and December 31, 2020, the balance of account receivables was $1,062,278 and $1,366,194, respectively. Approximately $0.9 million and $1.3 million of account receivables as of March 31, 2021 and December 31, 2020, respectively, was from DSS with a merchant agreement, under which the Company uses DSS credit card platform to collect money from our direct sales. The Company monitors its account receivables balances monthly to ensure that they are collectible. On a quarterly basis, the Company uses its historical experience to estimate its allowance for doubtful account receivables. The Company’s allowance for doubtful accounts represents an estimate of the losses expected to be incurred based on specifically identified accounts as well as nonspecific amount, when determined appropriate. Generally, the amount of the allowance is primarily decided by division management’s historical experience, the delinquency trends, the resolution rates, the aging of receivables, the credit quality indicators and financial health of specific customers. As of March 31, 2021 and December 31, 2020, the allowance was $0. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method and includes all costs in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs necessary to make the sale. As of March 31, 2021 and December 31, 2020, inventory consisted of finished goods from HWH World Inc. The Company continuously evaluates the need for reserve for obsolescence and possible price concessions required to write-down inventories to net realizable value. F- 8 Investment Securities Investment Securities at Fair Value The Company holds investments in equity securities with readily determinable fair values, equity investments without readily determinable fair values, investments accounted for under the equity method, and investments at cost. Prior to the adoption of Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities , investments in equity securities were classified as either 1) available-for-sale securities, stated at fair value, and unrealized holding gains and losses, net of related tax effects, were recorded directly to accumulated other comprehensive income (loss) or 2) trading securities, stated at fair value, and unrealized holding gains and losses, net of related tax benefits, were recorded directly to net income (loss). With the adoption of ASU 2016-01 on January 1, 2018, investments in equity securities are still stated at fair value, quoted by market prices, but all unrealized holding gains and losses are credited or charged to net income (loss) based on fair value measurement as the respective reporting date. The Company accounts for certain of its investments in equity securities in accordance with ASU 2016-01 Financial Instruments—Overall (Subtopic 825- 10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”) . In accordance with ASU 2016-01, the Company records all equity investments with readily determinable fair values at fair value calculated by the publicly traded stock price at the close of the reporting period. Amarantus BioScience Holdings (“AMBS”) and Ture Partner Capital Holding Limited (“True Partner”) are publicly traded companies. The Company does not have significant influence over AMBS and True Partner, as the Company is the beneficial owner of approximately 5.4% of the common shares of AMBS and 15.5% of True Partner. The stock’s fair value is determined by quoted stock prices. The Company has elected the fair value option for the equity securities noted below that would otherwise be accounted for under the equity method of accounting. Holista CollTech Limited (“Holista”), Document Securities Systems Inc. (“DSS”), OptimumBank Holdings, Inc. (“OptimumBank”) and American Premium Water Corp (“APW”) are publicly traded companies and fair value is determined by quoted stock prices. The Company has significant influence but does not have a controlling interest in these investments, and therefore, the Company’s investment could be accounted for under the equity method of accounting or elect fair value accounting. ● The Company has significant influence over DSS. As of March 31, 2021 and December 31, 2020, the Company owned the common stock of DSS and 42,575 shares of preferred stock, which could covert to 6,570,216 common shares, subject to a 19.9% beneficial ownership conversion limitation (a so-called “blocker”) based on the total issued outstanding shares of common stock of DSS beneficially owned by Global BioMedical Pte Ltd (“GBM”), one of our subsidiaries. Our CEO is a Stockholder and the Chairman of the Board of Directors of DSS. Chan Tung Moe, the son of Chan Heng Fai, is also a director of DSS. ● The Company has significant influence over Holista as the Company and its CEO are the beneficial owner of approximately 16.8% of the outstanding shares of Holista and our CEO holds a position on Holista’s Board of Directors. ● The Company has significant influence over OptimumBank. Our CEO is the beneficial owner of approximately 3.9% of the outstanding shares of OptimumBank and holds a position on OptimumBank’s Board of Directors. ● The Company has significant influence over APW as the Company is the beneficial owner of approximately 8.7% of the common shares of APW and one officer from the Company holds a director position on APW’s Board of Directors. F- 9 The Company invested $50,000 in a convertible promissory note of Sharing Services, Inc. (“Sharing Services Convertible Note”), a company quoted on the US OTC market. The value of the convertible note was estimated by management using a Black-Scholes valuation model. The fair value of the note was $64,991 and $66,978 on March 31, 2021 and December 31, 2020, respectively. On February 26, 2021, the Company invested approximately $88,599 in the convertible note of Vector Com Co., Ltd (“Vector Com”), a private company in South Korea. The interest rate is 2% per annum and maturity is two years. The conversion price is approximately $21.26, per common share of Vector Com. As of March 31, 2021, the Management estimated that the fair value of the note to be $88,599, the initial transaction price. On March 2, 2020, the Company received warrants to purchase shares of American Medical REIT Inc. (“AMRE”), a related party private startup company, in conjunction with the Company lending a $200,000 promissory note. For further details on this transaction, refer to Note 8 - Related Party Transactions, Note Receivable from a Related Party Company . As of March 31, 2021 and December 31, 2020, AMRE was a private company. Based on management’s analysis, the fair value of the AMRE warrants and the stock option was $0 as of March 31, 2021 and December 31, 2020. The Company held a stock option to purchase 250,000 shares of Vivacitas common stock at $1 per share at any time prior to the date of a public offering by Vivacitas. As of December 31, 2020, Vivacitas was a private company. Based on management’s analysis, the fair value of the Vivacitas stock option was $0 as of December 31, 2020. On March 18, 2021 the Company sold the subsidiary holding the ownership in Vivacitas to an indirect subsidiary of DSS. For further details on this transaction, refer to Note 9 - Related Party Transactions, Sale of Investment in Vivacitas to DSS . In the first quarter of 2021, the Company subsidiaries established a portfolio of trading securities. The objective is to generate profits on short-term differences in market prices. During the three months ended March 31, 2021, the Company incurred approximately $4.6 million in purchase of trading securities, received approximately $1.9 million for sale and $285,245 was recognized as realized loss on securities investment. Investment Securities at Cost The Company had an equity holding in Vivacitas Oncology Inc. (“Vivacitas”), a private company that is currently not listed on an exchange. Vivacitas was acquired after the adoption of ASU 2016-01. The Company applied ASC 321, Investments – Equity Securities, and elected the measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820 to estimate fair value using the NAV per share. Under the alternative, we measure Vivacitas at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Ownership in Vivacitas was sold on March 18, 2021 at the price of $2,480,000 to DSS. The difference of $2,279,872 between the selling price and our original investment cost was recorded as additional paid capital considering a related party transaction. For further details on this transaction, refer to Note 9 – Related Party Transactions. F- 10 On September 8, 2020, the Company acquired 1,666 shares, approximately 1.45% ownership, from Nervotec Pte Ltd (“Nervotec”), a private company, at the purchase price of $37,826. The Company applied ASC 321 and measured Nervotec at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. On September 30, 2020, the Company acquired 20,000 shares, approximately 19% ownership, from Hyten Global (Thailand) Co., Ltd (“Hyten”), a private company, at a purchase price of $42,562. Hyten is a direct sales company in Thailand. The Company does not have significant influence over Hyten and applied ASC 321 and measured Hyten at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. In the first quarter of 2021, the Company invested $19,609 in K Beauty Research Lab Co., Ltd (“K Beauty”) for 18% ownership. K Beauty was established for sourcing, developing and producing variety of Korea-made beauty products as well as Korea - originated beauty contents for the purpose of distribution to HWH’s membership distribution channel. There has been no indication of impairment or changes in observable prices via transactions of similar securities and investments are still carried at cost. Investment Securities under Equity Method Accounting American Medical REIT Inc. LiquidValue Asset Management Pte. Ltd. (“LiquidValue”), a subsidiary of the Company owns 36.1% of American Medical REIT Inc. (“AMRE”), a startup REIT company concentrating on medical real estate. AMRE acquires state-of-the-art, purpose-built healthcare facilities and leases them to leading clinical operators with dominant market share under secure triple net leases. AMRE targets hospitals (both Critical Access and Specialty Surgical), Physician Group Practices, Ambulatory Surgical Centers, and other licensed medical treatment facilities. Chan Heng Fai, our CEO, is the executive chairman and director of AMRE. LiquidValue did not invest equity but provided a loan to AMRE (for further details on this transaction, refer to Note 9, Related Party Transactions). On balance sheet, the prorate loss from AMRE was recorded as a liability, accumulated losses on equity method investment. During three months ended March 31, 2021 and 2020, the investment losses from AMRE were $24,847 and $0, respectively. As of March 31, 2021 and December 31, 2020, the accumulated losses on equity method investment were $290,776 and $265,929, respectively. Real Estate Assets Real estate assets are recorded at cost, except when real estate assets are acquired that meet the definition of a business combination in accordance with Financial Accounting Standards Board (“FASB”) ASC 805 - “Business Combinations”, which acquired assets are recorded at fair value. Interest, property taxes, insurance and other incremental costs (including salaries) directly related to a project are capitalized during the construction period of major facilities and land improvements. The capitalization period begins when activities to develop the parcel commence and ends when the asset constructed is completed. The capitalized costs are recorded as part of the asset to which they relate and are reduced when lots are sold. The Company capitalized construction costs of approximately $1.2 million and $2.4 million for the three months ended March 31, 2021 and 2020, respectively. The Company’s policy is to obtain an independent third-party valuation for each major project in the United States as part of our assessment of identifying potential triggering events for impairment. Management may use the market comparison method to value other relatively small projects, such as the project in Perth, Australia. In addition to the annual assessment of potential triggering events in accordance with ASC 360 – Property Plant and Equipment (“ASC 360”), the Company applies a fair value-based impairment test to the net book value assets on an annual basis and on an interim basis if certain events or circumstances indicate that an impairment loss may have occurred. F- 11 The Company did not record impairment on any of its projects during the three months ended on March 31, 2021 and 2020. Properties under development Properties under development are properties being constructed for sale in the ordinary course of business, rather than to be held for the Company’s own use, rental or capital appreciation. Rental Properties Rental properties are acquired with the intent to be rented to tenants. On March 15, 2021 Alset EHome, Inc. signed twenty separate Purchase Agreements, to acquire 20 homes in Montgomery County, Texas. On March 31, 2021, the first batch of 10 homes was closed with the purchase cost of $2,161,680. All of these purchased homes are properties of our rental business. Revenue Recognition and Cost of Sales ASC 606 - Revenue from Contracts with Customers (“ASC 606”), establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The Company adopted this new standard on January 1, 2018 under the modified retrospective method. The adoption of this new standard did not have a material effect on our financial statements. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which the determination of revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which the Company expects to be entitled in exchange for those goods or services. ASC 606 requires the Company to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, performance obligations are satisfied. F- 12 The following represents the Company’s revenue recognition policies by Segments: Property Development Property Sales The Company’s main business is land development. The Company purchases land and develops it for building into residential communities. The developed lots are sold to builders (customers) for the construction of new homes. The builders enter a sales contract with the Company before they take the lots. The prices and timeline are determined and agreed upon in the contract. The builders do the inspections to make sure all conditions and requirements in contracts are met before purchasing the lots. A detailed breakdown of the five-step process for the revenue recognition of the Ballenger and Black Oak projects, which represented approximately 69% and 100%, respectively, of the Company’s revenue in the three months ended on March 31, 2021 and 2020, is as follows: ● Identify the contract with a customer. The Company has signed agreements with the builders for developing the raw land to ready to build lots. The contract has agreed upon prices, timelines, and specifications for what is to be provided. ● Identify the performance obligations in the contract. Performance obligations of the Company include delivering developed lots to the customer, which are required to meet certain specifications that are outlined in the contract. The customer inspects all lots prior to accepting title to ensure all specifications are met. ● Determine the transaction price. The transaction price per lot is fixed and specified in the contract. Any subsequent change orders or price changes are required to be approved by both parties. ● Allocate the transaction price to performance obligations in the contract. Each lot or a group of lots is considered to be a separate performance obligation, for which the specified price in the contract is allocated to. ● Recognize revenue when (or as) the entity satisfies a performance obligation. The builders do the inspections to make sure all conditions/requirements are met before taking title of lots. The Company recognizes revenue at a point in time when title is transferred. The Company does not have further performance obligations or continuing involvement once title is transferred. Sale of the Front Foot Benefit Assessments We have established a front foot benefit (“FFB”) assessment on all of the NVR lots. This is a 30-year annual assessment allowed in Frederick County which requires homeowners to reimburse the developer for the costs of installing public water and sewer to the lots. These assessments become effective as homes are settled, at which time we can sell the collection rights to investors who will pay an upfront lump sum, enabling us to realize the revenue more quickly. The selling prices range from $3,000 to $4,500 per home depending on the type of the home. Our total revenue from the front foot benefit assessment is approximately $1 million. To recognize revenue of FFB assessment, both our and NVR’s performance obligation must be satisfied. Our performance obligation is completed once we complete the construction of water and sewer facility and close the lot sales with NVR, which inspects these water and sewer facility prior to close lot sales to ensure all specifications are met. NVR’s performance obligation is to sell homes they build to homeowners. Our FFB revenue is recognized on quarterly basis after NVR closes sales of homes to homeowners. The agreement with these FFB investors is not subject to amendment by regulatory agencies and thus our revenue from FFB assessment is not either. During the three months ended on March 31, 2021 and 2020, we recognized revenue $107,071 and $40,322 from FFB assessment, respectively. F- 13 Cost of Sales Land acquisition costs are allocated to each lot based on the area method, the size of the lot comparing to the total size of all lots in the project. Development costs and capitalized interest are allocated to lots sold based on the total expected development and interest costs of the completed project and allocating a percentage of those costs based on the selling price of the sold lot compared to the expected sales values of all lots in the project. If allocation of development costs and capitalized interest based on the projection and relative expected sales value is impracticable, those costs could also be allocated based on area method, the size of the lot comparing to the total size of all lots in the project. Biohealth Product Direct Sales The Company’s net sales consist of product sales. The Company’s performance obligation is to transfer its products to its third-party independent distributors (“Distributors”). The Company generally recognizes revenue when product is shipped to its Distributors. The Company’s Distributors may receive distributor allowances, which are comprised of discounts, rebates and wholesale commission payments from the Company. Distributor allowances resulting from the Company’s sales of its products to its Distributors are recorded against net sales because the distributor allowances represent discounts from the suggested retail price. In addition to distributor allowances, the Company compensates its sales leader Distributors with leadership incentives for services rendered, relating to the development, retention, and management of their sales organizations. Leadership incentives are payable based on achieved sales volume, which are recorded in general and administrative expenses. The Company recognizes revenue when it ships products. The Company receives the net sales price in cash or through credit card payments at the point of sale. If a Distributor returns a product to the Company on a timely basis, he/she may obtain a replacement product from the Company for such returned products. In addition, the Company maintains a buyback program pursuant to which it will repurchase products sold to a Distributor who has decided to leave the business. Allowances for product returns, primarily in connection with the Company’s buyback program, are provided at the time the sale is recorded. This accrual is based upon historical return rates for each country and the relevant return pattern, which reflects anticipated returns to be received over a period of up to 12 months following the original sale. Annual Membership The Company collects an annual membership fee from its Distributors. The fee is fixed, paid in full at the time of joining the membership and non-refundable. The membership provides the member access to purchase products at a discount, use to certain back-office services, receive commissions for signing up new members, and attend corporate events. The Company recognizes revenue associated with the membership over the period of the membership. Before the membership fee is recognized as revenue, it is recorded as deferred revenue. Deferred revenue relating to membership was $3,430,893 and $2,867,226 at March 31, 2021 and December 31, 2020, respectively. F- 14 Other Businesses Remaining performance obligations As of March 31, 2021 and December 31, 2020, there were no remaining performance obligations or continuing involvement, as all service obligations within the other business activities segment have been completed. Foreign currency Functional and reporting currency Items included in the financial statements of each entity in the Company are measured using the currency of the primary economic environment in which the entity operates (“functional currency”). The financial statements of the Company are presented in U.S. dollars (the “reporting currency”). The functional and reporting currency of the Company is the United States dollar (“U.S. dollar”). The financial records of the Company’s subsidiaries located in Singapore, Hong Kong, Australia and South Korea are maintained in their local currencies, the Singapore Dollar (S$), Hong Kong Dollar (HK$), Australian Dollar (“AUD”) and South Korean Won (“KRW”), which are also the functional currencies of these entities. Transactions in foreign currencies Transactions in currencies other than the functional currency during the periods are converted into functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the statement of operations. The majority of the Company’s foreign currency transaction gains or losses come from the effects of foreign exchange rate changes on the intercompany loans between Singapore entities and U.S. entities. The Company recorded foreign exchange gain of $1,462,697 and $2,260,482 during the three months ended on March 31, 2021 and 2020, respectively. The foreign currency transactional gains and losses are recorded in operations. Translation of consolidated entities’ financial statements Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the rates of exchange ruling at the balance sheet date. The Company’s entities with functional currency of Singapore Dollar, Hong Kong Dollar, AUD and KRW, translate their operating results and financial positions into the U.S. dollar, the Company’s reporting currency. Assets and liabilities are translated using the exchange rates in effect on the balance sheet date. Revenue, expense, gains and losses are translated using the average rate for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of comprehensive income (loss). For the three months ended on March 31, 2021, the Company recorded other comprehensive loss from foreign currency translation of $1,769,440 and a $1,674,021 loss in the three months ended March 31, 2020, in accumulated other comprehensive loss. F- 15 Non-controlling interests Non-controlling interests represent the equity in subsidiary not attributable, directly or indirectly, to owners of the Company, and are presented separately in the consolidated statements of operation and comprehensive income, and within equity in the Consolidated Balance Sheets, separately from equity attributable to owners of the Company. On March 31, 2021 and December 31, 2020, the aggregate non-controlling interests in the Company were $33,673,855 and $37,980,325, respectively. Capitalized Financing Costs Financing costs, such as loan origination fee, administration fee, interests and other related financing costs, should be capitalized and recorded on the balance sheet if these financing activities are directly associated with the development of real estates. Capitalized Financing Costs are allocated to lots sold based on the total expected development and interest costs of the completed project and allocating a percentage of those costs based on the selling price of the sold lot compared to the expected sales values of all lots in the project. If the allocation of capitalized financing costs based on the projection and relative expected sales value is impracticable, those costs could also be allocated based on an area method, which uses the size of the lots compared to the total project area and allocates costs based on their size. As of March 31, 2021 and December 31, 2020, the capitalized financing costs were $3,348,112 and $3,513,535, respectively. Beneficial Conversion Features The Company evaluates the conversion feature for whether it was beneficial as described in ASC 470-30. The intrinsic value of a beneficial conversion feature inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the date the note is due using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the beneficial conversion feature is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the shares of common stock at the commitment date to be received upon conversion. Recent Accounting Pronouncements Accounting pronouncement not yet adopted In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach is required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. In November of 2019, the FASB issued ASU 2019-10, which delayed the implementation of ASU 2016-13 to fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company is currently evaluating the impact of ASU 2016-13 on its future consolidated financial statements. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of Reference Rate Reform on Financial Reporting . The amendments in this Update provide optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this Update apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The Company’s line of credit agreement provides procedures for determining a replacement or alternative rate in the event that LIBOR is unavailable. The amendments in this Update are effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-04 on its future consolidated financial statements. F- 16 3. CONCENTRATIONS The Company maintains cash balances at various financial institutions in different countries. These balances are usually secured by the central banks’ insurance companies. At times, these balances may exceed the insurance limits. As of March 31, 2021 and December 31, 2020, uninsured cash and restricted cash balances were $26,238,531 and $25,752,637, respectively. For the three months ended March 31, 2021, two customers accounted for approximately 97%, and 3% of the Company’s property and development revenue. For the three months ended March 31, 2020, two customers accounted for approximately 99%, and 1% of the Company’s property and development revenue. 4. SEGMENTS Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision–making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision-maker is the CEO. The Company operates in and reports four business segments: property development, digital transformation technology, biohealth, and other business activities. The Company’s reportable segments are determined based on the services they perform and the products they sell, not on the geographic area in which they operate. The Company’s chief operating decision maker evaluates segment performance based on segment revenue. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative activities which are not allocable to the four reportable segments. The following table summarizes the Company’s segment information for the following balance sheet dates presented, and for the three months ended March 31, 2021 and 2020: Property Development Digital Transformation Technology Biohealth Business Other Total Three Months Ended March 31, 2021 Revenue $ 3,894,131 $ - $ 1,712,783 $ - $ 5,606,914 Cost of Sales (3,614,832 ) - (83,022 ) - (3,697,854 ) Gross Margin 279,299 - 1,629,761 - 1,909,060 Operating Expenses (359,489 ) (30,128 ) (846,480 ) (1,076,408 ) (2,312,505 ) Operating Income (Loss) (80,190 ) (30,128 ) 783,281 (1,076,408 ) (403,445 ) Other Income (Expense) (9,873 ) (36,471 ) (8,371,117 ) (532,505 ) (8,949,966 ) Net Income (Loss) Before Income Tax (90,063 ) (66,599 ) (7,587,836 ) (1,608,913 ) (9,353,411 ) Property Development Digital Transformation Technology Biohealth Business Other Total Three Months ended March 31, 2020 Revenue $ 2,954,389 $ - $ 10,782 $ - $ 2,965,171 Cost of Sales (2,380,820 ) - (2,883 ) - (2,383,703 ) Gross Margin 573,569 - 7,899 - 581,468 Operating Expenses (277,056 ) (18,228 ) (132,791 ) (575,784 ) (1,003,859 ) Operating Income (Loss) 296,513 (18,228 ) (124,892 ) (575,784 ) (422,391 ) Other Income (Expense) 7,539 (92,477 ) 193 2,762,701 2,677,956 Net Income (Loss) Before Income Tax 304,052 (110,705 ) (124,699 ) 2,186,917 2,255,565 March 31, 2021 Cash and Restricted Cash $ 9,842,218 $ 154,738 $ 3,251,622 $ 15,756,505 $ 29,005,083 Total Assets 30,877,470 154,840 43,241,793 34,523,886 108,797,989 December 31, 2020 Cash and Restricted Cash $ 8,150,769 $ 158,058 $ 1,590,265 $ 21,336,364 $ 31,235,456 Total Assets 28,954,484 158,160 524,603 77,574,674 107,211,921 F- 17 5. BUSINESS UNDER COMMON CONTROL Due to the transactions with Chan Heng Fai on March 12, 2021, transactions between entities under common control ( for further details on these transactions, refer to Note 2 – Summary of Significant Accounting Policies) , the Company has disclosed the Consolidated Statement of Operations and Other Comprehensive Income for the Three Months Ended on March 31, 2020 and Consolidated Balance Sheet as of December 31, 2020, to adjust the information on a consolidated basis as follows: Consolidated Statement of Operations and Other Comprehensive Income for the Three Months Ended on March 31, 2020 As Previously Reported Acquisition of APB under Common Control Acquisition of LVD Ltd under Common Control As Combined Revenue Property Sales $ 2,954,389 $ - $ - $ 2,954,389 Biohealth Product Sales 10,782 - - 10,782 2,965,171 - - 2,965,171 Operating Expenses Cost of Sales 2,383,703 - - 2,383,703 General and Administrative 920,124 81,226 500 1,001,850 Research and Development 2,009 - - 2,009 Total Operating Expenses 3,305,836 81,226 500 3,387,562 Loss From Operations (340,665 ) (81,226 ) (500 ) (422,391 ) Other Income (Expense) Interest Income 7,810 11,580 25 19,415 Interest Expense (60,931 ) - - (60,931 ) Foreign Exchange Transaction Gain (Loss) 2,118,952 - 141,530 2,260,482 Unrealized Gain (Loss) on Securities Investment 484,362 (26,034 ) 94 458,422 Finance Costs - (4,890 ) (13 ) (4,903 ) Other Income 5,471 - - 5,471 Total Other Income (Expense), Net 2,555,664 (19,344 ) 141,636 2,677,956 Net Income (Loss) Before Income Taxes 2,214,999 (100,570 ) 141,136 2,255,565 Income Tax - - - - Net Income (Loss) 2,214,999 (100,570 ) 141,136 2,255,565 Net Income (Loss) Attributable to Non-Controlling Interest 643,139 (6,436 ) - 636,703 Net Income (Loss) Attributable to Common Stockholders $ 1,571,860 $ (94,134 ) $ 141,136 $ 1,618,862 Other Comprehensive Loss, Net Unrealized Loss on Securities Investment (12,599 ) - - (12,599 ) Foreign Currency Translation Adjustment (1,674,021 ) - - (1,674,021 ) Comprehensive Income (Loss) 528,379 (100,570 ) 141,136 568,945 Comprehensive Income (Loss) Attributable to Non-controlling Interests 59,569 (6,436 ) - 53,133 Comprehensive Income (Loss) Attributable to Common Stockholders $ 468,810 $ (94,134 ) $ 141,136 $ 515,812 Net Income Per Share - Basic and Diluted $ 0.16 $ 0.16 Weighted Average Common Shares Outstanding - Basic and Diluted 10,001,000 10,001,000 F- 18 Consolidated Balance Sheet as of December 31, 2020 As Previously Reported Acquisition of APB under Common Control Acquisition of LVD Ltd under Common Control Eliminations As Combined Assets: Current Assets: Cash $ 22,124,491 $ 1,848,455 $ 492,977 $ - $ 24,465,923 Restricted Cash 6,769,533 - - - 6,769,533 Account Receivables, Net 1,366,194 - - - 1,366,194 Other Receivables 270,222 279,177 95,177 - 644,576 Note Receivables - Related Party 624,986 24,583 - - 649,569 Prepaid Expenses 1,470,680 - - - 1,470,680 Inventory 90,068 - - - 90,068 Investment in Securities at Fair Value 48,857,483 313,343 1,631 - 49,172,457 Investment in Securities at Cost 280,516 - - - 280,516 Investment in Securities on Equity Method - - 74,535 (74,535 ) - Deposits 47,019 - - - 47,019 Total Current Assets 81,901,192 2,465,558 664,320 (74,535 ) 84,956,535 Real Estate Properties under Development 20,505,591 - - - 20,505,591 Operating Lease Right-Of-Use Asset 574,754 - - - 574,754 Deposit 249,676 - - - 249,676 Loan Receivable - 840,000 - - 840,000 Property and Equipment, Net 85,365 - - - 85,365 Total Assets $ 103,316,578 $ 3,305,558 $ 664,320 $ (74,535 ) $ 107,211,921 Liabilities and Stockholders’ Equity: Current Liabilities: Accounts Payable and Accrued Expenses $ 1,553,132 $ 117,188 $ - $ - $ 1,670,320 Deferred Revenue 2,867,226 - - - 2,867,226 Builder Deposits 1,262,336 - - - 1,262,336 Operating Lease Liability 381,412 - - - 381,412 Note Payable 172,706 - - - 172,706 Note Payable- Related Parties 1,526,208 - 823,823 - 2,350,031 Total Current Liabilities 7,763,020 117,188 823,823 - 8,704,031 Long-Term Liabilities: Builder Deposits - - - - - Operating Lease Liability 193,342 - - - 193,342 Notes Payable 636,362 - - - 636,362 Total Liabilities 8,592,724 117,188 823,823 - 9,533,735 Stockholders’ Equity: Common Stock 8,570 47,756 - (47,756 ) 8,570 Additional Paid In Capital 97,950,440 3,584,982 756,487 47,756 102,339,666 Accumulated Deficit (43,010,991 ) (876,712 ) (906,010 ) - (44,793,713 ) Accumulated Other Comprehensive Income 2,153,318 - (9,980 ) - 2,143,338 Total Stockholders’ Equity 57,101,337 2,756,027 (159,503 ) - 59,697,861 Non-controlling Interests 37,622,517 432,343 - (74,535 ) 37,980,325 Total Stockholders’ Equity 94,723,854 3,188,370 (159,503 ) (74,535 ) 97,678,186 Total Liabilities and Stockholders’ Equity $ 103,316,578 $ 3,305,558 $ 664,320 $ (74,535 ) $ 107,211,921 F- 19 6. REAL ESTATE ASSETS As of March 31, 2021 and December 31, 2020, real estate assets consisted of the following: March 31, 2021 December 31, 2020 Construction in Progress $ 7,465,347 $ 9,567,841 Land Held for Development 10,638,686 10,937,750 Rental Properties 2,161,680 - Total Real Estate Assets $ 20,265,713 $ 20,505,591 7. BUILDER DEPOSITS In November 2015, SeD Maryland Development, LLC (“SeD Maryland”) entered into lot purchase agreements with NVR, Inc. (“NVR”) relating to the sale of single-family home and townhome lots to NVR in the Ballenger Run Project. The purchase agreements were amended three times thereafter. Based on the agreements, NVR is entitled to purchase 479 lots for a price of approximately $64,000,000, which escalates 3% annually after June 1, 2018. As part of the agreements, NVR was required to give a deposit in the amount of $5,600,000. Upon the sale of lots to NVR, 9.9% of the purchase price is taken as payback of the deposit. A violation of the agreements by NVR would cause NVR to forfeit the deposit. On January 3, 2019 and April 28, 2020, NVR gave SeD Maryland two more deposits in the amounts of $100,000 and $220,000, respectively, based on the 3rd Amendment to the Lot Purchase Agreement. On March 31, 2021 and December 31, 2020, there were $928,565 and $1,262,336 held on deposit, respectively. 8. NOTES PAYABLE As of March 31, 2021 and December 31, 2020, notes payable consisted of the following: March 31, 2021 December 31, 2020 M&T Bank Loan, Net of Debt Discount 651,034 636,362 PPP Loan 68,502 - Australia Loan 170,433 172,706 Total notes payable $ 889,969 $ 809,068 M&T Bank Loan On April 17, 2019, SeD Maryland Development LLC entered into a Development Loan Agreement with Manufacturers and Traders Trust Company (“M&T Bank”) in the principal amount not to exceed at any one time outstanding the sum of $8,000,000, with a cumulative loan advance amount of $18,500,000. The line of credit bears interest rate on LIBOR plus 375 basis points. SeD Maryland Development LLC was also provided with a Letter of Credit (“L/C”) Facility in an aggregate amount of up to $900,000. The L/C commission will be 1.5% per annum on the face amount of the L/C. Other standard lender fees will apply in the event L/C is drawn down. The loan is a revolving line of credit. The L/C Facility is not a revolving loan, and amounts advanced and repaid may not be re-borrowed. Repayment of the Loan Agreement is secured by $2,600,000 collateral fund and a Deed of Trust issued to the Lender on the property owned by SeD Maryland. As of March 31, 2021, the outstanding balance of the revolving loan was $0. As part of the transaction, the Company incurred loan origination fees and closing fees in the amount of $381,823 and capitalized it into construction in process. On June 18, 2020, Alset EHome Inc. (“Alset EHome”), a wholly owned subsidiary of LiquidValue Development Inc., entered into a Loan Agreement with Manufacturers and Traders Trust Company (the “Lender”). F- 20 Pursuant to the Loan Agreement, the Lender provided a non-revolving loan to Alset EHome in an aggregate amount of up to $2,990,000 (the “Loan”). The line of credit bears interest rate on LIBOR plus 375 basis points. Repayment of the Loan is secured by a Deed of Trust issued to the Lender on the property owned by certain subsidiaries of Alset EHome. The maturity date of this Loan is July 1, 2022. LiquidValue Development Inc. and one of its subsidiaries are guarantors of this Loan. The guarantors are required to maintain during the term of the loan a combined minimum net worth in an aggregate amount equal to not less than $20,000,000. The Company was in compliance with this covenant as of December 31, 2020 and March 31,2021. During the year ended December 31, 2020 Alset EHome borrowed $664,810 from M&T Bank, incurring at the same time a loan origination fees of $61,679 which are to be amortized over the term of the loan. Alset EHome didn’t borrow any additional funds in three months ended on March 31, 2021. In the three months ended March 31, 2021 and 2020, Alset EHome expensed $6,627 and $0, respectively, in interest on this loan and recorded $8,045 and $0, respectively, of amortization expense. As of March 31, 2021 and December 31, 2020, the remaining unamortized debt discount was $34,862 and $42,906, respectively. Paycheck Protection Program Loan On February 11, 2021, the Company entered into a five year note with M&T Bank with a principal amount of $68,502 pursuant to the Paycheck Protection Program (“PPP Term Note”) under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The PPP Loan is evidenced by a promissory note. The PPP Term Note bears interest at a fixed annual rate of 1.00%, with the first sixteen months of principal and interest deferred or until we apply for the loan forgiveness. The PPP Term Note may be accelerated upon the occurrence of an event of default. The PPP Term Note is unsecured and guaranteed by the United States Small Business Administration. The Company may apply to M&T Bank for forgiveness of the PPP Term Note, with the amount which may be forgiven equal to at least 60% of payroll costs and other eligible payments incurred by the Company, calculated in accordance with the terms of the CARES Act. At this time, we are not in a position to quantify the portion of the PPP Term Note that will be forgiven. As of March 31, 2021, we owned $68,502 to M&T Bank. Australia Loan On January 7, 2017, SeD Perth Pty Ltd (“SeD Perth”) entered into a loan agreement with National Australian Bank Limited (the “Australia Loan”) for the purpose of funding land development. The loan facility provides SeD Perth with access to funding of up to approximately $460,000 and matures on December 31, 2018. The Australia Loan is secured by both the land under development and a pledged deposit of $35,276. This loan is denominated in AUD. Personal guarantees amounting to approximately $500,000 have been provided by our CEO, Chan Heng Fai and by Rajen Manicka, the CEO of Holista CollTech and Co-founder of iGalen Inc. The interest rate on the Australia Loan is based on the weighted average interest rates applicable to each of the business markets facility components as defined within the loan agreement, ranging from 4.12% to 4.58% per annum for the three months ended March 31, 2021 and from 4.85% to 5.57% per annum for the three months ended March 31, 2020. On September 7, 2017 the Australia Loan was amended to reduce the maximum borrowing capacity to approximately $179,000. During 2020, the terms of the Australia Loan were amended to reflect an extended maturity date of April 30, 2022. This was accounted for as a debt modification. The Company did not pay fees to the National Australian Bank Limited for the modification of the loan agreement. 9. RELATED PARTY TRANSACTIONS Personal Guarantees by Directors As of March 31, 2021 and December 31, 2020, a director of the Company had provided personal guarantees amounting to approximately $500,000, to secure external loans from financial institutions for AEI and the consolidated entities. F- 21 Sale of Investment in Vivacitas to DSS On March 18, 2021, the Company sold equity investment in Vivacitas, a U.S.-based biopharmaceutical company, equaling to 2,480,000 shares of common stock and a stock option to purchase 250,000 shares of Vivacitas common stock at $1 per share at any time prior to the date of a public offering, to a subsidiary of DSS for $2,480,000. Chan Heng Fai, CEO and the founder of the Company, holds a director position on both Vivacitas and DSS. After this transaction, we do not own any investment in Vivacitas. Our original cost of common stock and stock option of Vivacitas was $200,128. We did not recognize gain or loss in this transaction. The difference of $2,279,872 between the selling price and our original investment cost was recorded as additional paid capital considering it was a related party transaction. Notes Payable Chan Heng Fai provided interest-free, due on demand advance to LiquidValue Development Pte. Ltd. and its subsidiary LiquidValue Development Limited of approximately $815,381 for the general operations. On March 31, 2021 and December 31, 2020, the outstanding balance was approximately $815,381 and $823,823, respectively. Chan Heng Fai provided interest-free, due on demand advance to Alset EHome International for the general operations. On March 31, 2021 and December 31, 2020, the outstanding balance was $178,400. Chan Heng Fai provided an interest-free, due on demand advance to SeD Perth Pty. Ltd. for its general operations. On March 31, 2021 and December 31, 2020, the outstanding balance was $14,190 and $14,379, respectively. On August 20, 2020, the Company acquired 30,000,000 common shares from Chan Heng Fai in exchange for a two-year non-interest bearing note of $1,333,429. On March 31, 2021 and December 31, 2020 the amount outstanding was $ 133,429 and $1,333,429, respectively. On March 12, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with Chan Heng Fai, the founder, Chairman and Chief Executive Officer of the Company, for four proposed transactions, consisting of (i) purchase of certain warrants (the “Warrants”) to purchase 1,500,000,000 shares of Alset International Limited (“Alset International”), which was valued at $28,363,966; (ii) purchase of all of the issued and outstanding stock of LiquidValue Development Pte Ltd. (“LVD”), which was valued at $173,395; (iii) purchase of 62,122,908 ordinary shares in True Partners Capital Holding Limited (HKG: 8657) (“True Partners”), which was valued at $6,729,629; and (iv) purchase of 4,775,523 shares of the common stock of American Pacific Bancorp Inc. (“APB”), which was valued at $28,653,138. The total amount of above four transactions was $63,920,129, payable on the Closing Date by the Company, in the convertible promissory notes (“Alset CPNs”), which, subject to the terms and conditions of the Alset CPNs and the Company’s shareholder approval, shall be convertible into shares of the Company’s common stock (“AEI Common Stock”), at par value of $0.001 per share, at the conversion price of AEI’s Stock Market Price. AEI’s Stock Market Price shall be $5.59 per share, equivalent to the average of the five closing per share prices of AEI Common Stock preceding January 4, 2021 as quoted by Bloomberg L.P. AEI stock price was $10.03 on March 12, 2021, the commitment date. The Beneficial Conversion Feature (“BCF”) intrinsic value was $50,770,192 for the four convertible promissory notes and was recorded as debt discount of convertible notes after the transaction. As of March 31, 2021, the promissory notes net of debt discount were $13,695,852 and accrued interest was $41,239. F- 22 Management Fees MacKenzie Equity Partners, owned by Charles MacKenzie, a Director of the Company’s subsidiary LiquidValue Development, has had a consulting agreement with the Company since 2015. Per the terms of the agreement, as amended on January 1, 2018, the Company has paid a monthly fee of $20,000 for these consulting services. The Company incurred expenses of $60,000 and $60,000 for the three months ended March 31, 2021 and 2020, respectively, which were capitalized as part of Real Estate on the Company’s Consolidated Balance Sheet as the services relate to property and project management. As of March 31, 2021, and December 31, 2020 the Company owed $0 to this entity. Consulting Services Chan Tung Moe was engaged as a consultant by the Company through Pop Motion Consulting Pte. Ltd. Chan Tung Moe is the son of Chan Heng Fai, the Chairman and CEO of our Company. In August of 2020, this consulting agreement was terminated, and Chan Tung Moe became an employee of Alset International as Chief Development Officer. Chan Tung Moe was appointed as Executive Director of Alset International Limited on December 11, 2020 and on March 1, 2021, he was appointed as Co-Chief Executive Officer of Alset International Limited. The Company incurred expense of $0 and $57,931 for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021 and December 31, 2020, the Company owed Pop Motion a consulting fee of $0. Notes Receivable from Related Party Companies On March 2, 2020 LiquidValue Asset Management Pte. Ltd. (“LiquidValue”) received a $200,000 Promissory Note from American Medical REIT Inc. (“AMRE”), a company which is 36.1% owned by LiquidValue. Chan Heng Fai and Chan Tung Moe from Alset International are directors of American Medical REIT Inc. The note carries interests of 8% and is payable in two years. LiquidValue also received warrants to purchase AMRE shares at the Exercise Price $5.00 per share. The amount of the warrants equals to the note principle divided by the Exercise Price. If AMRE goes to IPO in the future and IPO price is less than $10.00 per share, the Exercise price shall be adjusted downward to fifty percent (50%) of the IPO price. As of March 31, 2021 and December 31, 2020, the fair market value of the warrants was $0. The Company accrued $17,431 and $13,431 interest income as of March 31, 2021 and December 31, 2020, respectively. On January 24, 2017, SeD Capital Pte Ltd, a 100% owned subsidiary of Alset International lent $350,000 to iGalen. The term of the loan was two years, with an interest rate of 3% per annum for the first of year and 5% per annum for the second year. The expiration term was renewed as due on demand after two years with 5% per annum interest rate. As of March 31, 2021 and December 31, 2020, the outstanding principle was $350,000 and accrued interest was $62,058 and $61,555, respectively. As of March 31, 2021, the Company provided advances for operation of $10,104 to Hyten, a direct sales company in Thailand of which the Company holds approximately 19% ownership. The Company provided advances for operation of $29,968 to APW, a related party company of which the Company holds 8.7% ownership. Loan to Employees On November 24, 2020, American Pacific Bancorp. Inc. lent $560,000 to Chan Tung Moe, an officer of one of the subsidiaries of the Company and son of Chan Heng Fai, Chairman and Chief Executive Officer of the Company, bearing interest at 6%, with a maturity date of November 23, 2023. This loan is secured by an irrevocable letter of instruction on 80,000 shares of Alset EHome International. On November 24, 2020, American Pacific Bancorp. Inc. lent $280,000 to Lim Sheng Hon Danny, an employee of one of the subsidiaries of the Company, bearing interest at 6%, with a maturity date of November 23, 2023. This loan is secured by an irrevocable letter of instruction on 40,000 shares of Alset EHome International. As of December 31, 2020 and March 31, 2021, the accrued interest was $17,536 and $5,109, respectively. On March 12, 2021, the Company entered into a Securities Purchase Agreement pursuant to which the Company acquired 86.44% of the total issued and outstanding common stock of American Pacific Bancorp. Inc. F- 23 10. EQUITY The Company is authorized to issue 20,000,000 common shares and 5,000,000 preferred shares, both at a par value $0.001 per share. As of December 31, 2020, there were 8,570,000 common shares issued and outstanding. On January 19, 2021, the Company issued 10,000 shares of its common stock as compensation for public relations services at a fair value of $60,900. On March 31, 2021, there were 8,580,000 common shares issued and outstanding. On November 23, 2020, under the terms of the Underwriting Agreement, the Company issued to Aegis Capital Corp a warrant (the “Representative’s Warrant”) to purchase an aggregate of 108,000 shares of common stock. The Representative’s Warrant is exercisable at a per share price of $9.80 and is exercisable at any time and from time to time, in whole or in part, during the three-year period commencing from the date of issuance. Following table summarizes the warrant activity for the three months ended March 31, 2021. Warrant for Remaining Contractual Aggregate Common Shares Exercise Price Term (Years) Intrinsic Value Outstanding as of December 31, 2020 108,000 $ 9.80 2.95 $ - Vested and exercisable at December 31, 2020 108,000 $ 9.80 2.95 $ - Granted - - Exercised - - Forfeited, cancelled, expired - - Outstanding as of March 31, 2021 108,000 $ 9.80 2.70 $ 191,160 Vested and exercisable at March 31, 2021 108,000 $ 9.80 2.70 $ 191,160 GigWorld Inc. Sale of Shares From January to March, 2021, the Company sold 250,000 shares of GigWorld to international investors for the amount of $250,000, which was booked as addition paid-in capital. The Company held 505,551,376 shares of the total outstanding shares 506,898,576 before the sale. After the sale, the Company still owns approximately 99% of GigWorld’s total outstanding shares. From January to March, 2020, the Company sold 10,000 shares of GigWorld to international investors for the amount of $5,000, which was booked as addition paid-in capital. The Company held 506,223,676 shares of the total outstanding shares 506,898,576 before the sale. After the sale, the Company still owns approximately 99% of GigWorld’s total outstanding shares. During the three months ended March 31, 2021 and 2020, the sales of GigWorld’s shares were de minimis compared to its outstanding shares and did not change the minority interest. Distribution to Minority Shareholder During three months ended on March 31, 2021, SeD Maryland Development LLC Board approved the payment distribution plan to members and paid $82,250 in distribution to the minority shareholder. During three months ended on March 31, 2020, SeD Maryland Development LLC Board approved the payment distribution plan to members and paid $197,400 in distribution to the minority shareholder. F- 24 Changes of Ownership of Alset International In the three months ended March 31, 2021, Alset International issued 250,000 common shares through warrants exercise with exercise price of approximately $0.03 per share and received $7,484 cash. During the three months ended March 31, 2021, the stock-based compensation expense of Alset International was $73,292 with the issuance of 1,500,000 shares to an officer. The Company’s ownership of Alset International changed from 57.1% as of December 31, 2020 to 57.1% as of March 31, 2021. A subsidiary Issuing Stock During March, 2020, a subsidiary of the Company started a private offer (the “Private Offer”) of its units. Each unit comprised of one share of its Class A Common Stock with par value of $0.01 per share and its one Series A 5% Cumulative Preferred Stock with a par value of $0.01 per share, at a subscription price of $6 per unit. The net proceeds from the private offer were $2,232,491 from investors as of March 31, 2020. 11. ACCUMULATED OTHER COMPREHENSIVE INCOME Following is a summary of the changes in the balances of accumulated other comprehensive income, net of tax: Unrealized Gains and Losses on Security Investment Foreign Currency Translations Change in Minority Interest Total Balance at January 1, 2021 $ (48,758 ) $ 2,258,017 $ (65,921 ) $ 2,143,338 Other Comprehensive Income (1,135 ) (1,010,527 ) (39,067 ) (1,050,729 ) Balance at March 31, 2021 $ (49,893 ) $ 1,247,490 $ (104,988 ) $ 1,092,609 Unrealized Gains and Losses on Security Investment Foreign Currency Translations Change in Minority Interest Total Balance at January 1, 2020 $ (59,888 ) $ 1,603,145 $ (84,968 ) $ 1,458,289 Other Comprehensive Income (8,240 ) (1,094,810 ) - (1,103,050 ) Balance at March 31, 2020 $ (68,128 ) $ 508,335 $ (84,968 ) $ 355,239 12. INVESTMENTS MEASURED AT FAIR VALUE Financial assets measured at fair value on a recurring basis are summarized below and disclosed on the consolidated balance sheet as of March 31, 2021 and December 31, 2020: Amount at Fair Value Measurement Using Amount at Cost Level 1 Level 2 Level 3 Fair Value March 31, 2021 Assets Investment Securities- Fair Value $ 14,134,540 $ 17,923,989 $ - $ - $ 17,923,989 Investment Securities- Trading 2,457,162 2,468,809 - - 2,468,809 Convertible Preferred Stock 42,889,000 - - 29,430,000 29,430,000 Convertible Note Receivable 138,599 - - 153,590 153,590 Warrants - American Premium Water 860,342 - - 2,188,264 2,188,264 Warrants - AMRE - - - - - Total Investment in securities at Fair Value $ 60,479,643 $ 20,392,798 $ - $ 31,771,854 $ 52,164,652 F- 25 Amount at Fair Value Measurement Using Amount at Cost Level 1 Level 2 Level 3 Fair Value December 31, 2020 Assets Investment securities- Fair Value Option $ 7,404,911 $ 10,549,102 $ - $ - $ 10,549,102 Investment securities- Trading 17,650 18,654 - - 18,654 Convertible preferred stock 42,889,000 - - 37,675,000 37,675,000 Convertible note receivable 50,000 - - 66,978 66,978 Warrants - American Premium Water 860,342 - - 862,723 862,723 Warrants - AMRE - - - - - Stock Options - Vivacitas - - - - - Total Investment in securities at Fair Value $ 51,221,903 $ 10,567,756 $ - $ 38,604,701 $ 49,172,457 Unrealized loss on investment securities for the three months ended March 31, 2021 and 2020 was $1,987 and $12,599, respectively. These losses were recorded directly to net income (loss). For U.S. trading stocks, we use Bloomberg Market stock prices as the share prices to calculate fair value. For overseas stock, we use the stock price from local stock exchange to calculate fair value. The following chart shows details of the fair value of equity security investment at March 31, 2021 and December 31, 2020, respectively. Share price Market Value 3/31/2021 Shares 3/31/2021 Valuation DSS (Related Party) $ 3.610 1162501 * $ 4,196,629 Investment in Securities at Fair Value AMBS (Related Party) $ 0.011 20,000,000 $ 228,000 Investment in Securities at Fair Value Holista (Related Party) $ 0.049 46,226,673 $ 2,285,838 Investment in Securities at Fair Value American Premium Water (Related Party) $ 0.008 122,039,000 $ 1,025,128 Investment in Securities at Fair Value OptimumBank (Related Party) $ 3.870 92,980 $ 359,833 Investment in Securities at Fair Value True Partners $ 0.158 62,122,908 $ 9,828,563 Investment in Securities at Fair Value Trading Stocks $ 2,468,809 Investment in Securities at Fair Value Total Level 1 Equity Securities $ 20,392,798 Nervotech N/A 1,666 $ 37,826 Investment in Securities at Cost Hyten Global N/A 20,000 $ 42,562 Investment in Securities at Cost K Beauty N/A 3,600 $ 19,609 Investment in Securities at Cost Total Equity Securities $ 20,492,795 F- 26 Share price Market Value 12/31/2020 Shares 12/31/2020 Valuation DSS (Related Party) $ 6.240 1,162,501 * $ 7,254,006 Investment in Securities at Fair Value AMBS (Related Party) $ 0.008 20,000,000 $ 160,000 Investment in Securities at Fair Value Holista (Related Party) $ 0.055 46,226,673 $ 2,565,469 Investment in Securities at Fair Value American Premium Water (Related Party) $ 0.002 122,039,000 $ 256,284 Investment in Securities at Fair Value OptimumBank (Related Party) $ 3.370 92,980 $ 313,343 Investment in Securities at Fair Value Trading Stocks $ 18,654 Investment in Securities at Fair Value Total Level 1 Equity Securities $ 10,567,756 Vivacitas (Related Party) N/A 2,480,000 $ 200,128 Investment in Securities at Cost Nervotech N/A 1,666 $ 37,826 Investment in Securities at Cost Hyten Global N/A 20,000 $ 42,562 Investment in Securities at Cost Total Equity Securities $ 10,848,272 * Ratio of 1-for-30 (the “Reverse Split”) was effective at 5:01 p.m. Eastern Time on May 7, 2020 (the “Effective Time”) DSS convertible preferred stock The DSS convertible preferred stock under level 3 category was valued on Option Pricing Method (OPM) in determining the fair value. As of March 31, 2021, the Company held 42,575 shares of DSS convertible preferred stock, which could convert to 6,570,216 common shares, with fair market value of $29,430,000. As of December 31, 2020, the Company held 42,575 shares of DSS convertible preferred stock, which could convert to 6,570,216 common shares, with fair market value $37,675,000. The following table shows the parameters adopted in the valuation at the valuation dates. As of March 31, As of December 31, 2021 2020 Stock price $ 4.22 $ 6.24 Risk-free rate 1.64 % 0.93 % Volatility 109.67 % 113.69 % Expected Exit Date March 24, 2023 December 31, 2023 Dividend Yield 0.00 0.00 The selected stock prices represent the close market bid price of DSS on the valuation date. Risk-free interest rates were obtained from Bloomberg. The volatility is based on the historical volatility of the DSS common stock. We assumed a three-year life for the preferred stock and assumed that after three-years the Company would desire to begin receiving a return on this investment – either through a conversion or liquidation. Given the Beneficial Ownership limited on the exercise of the Series A Preferred Shares, we have assumed that Alset International will sell their common stocks in the Target Company such that their shareholding does not exceed 19.99% prior to conversion. We have assessed the Discount for Lack of Marketability (DLOM) of this interest using a put option method and adopted Black-Scholes Option Pricing Model to estimate the DLOM. F- 27 Sharing Services Convertible Note The fair value of the Sharing Services Convertible Note under level 3 category as of March 31, 2021 and December 31, 2020 was calculated using a Black-Scholes valuation model valued with the following weighted average assumptions: March 31, 2021 December 31, 2020 Dividend yield 0.00 % 0.00 % Expected volatility 210.07 % 210.07 % Risk free interest rate 3.25 % 0.13 % Contractual term (in years) 1.51 1.76 Exercise price $ 0.15 $ 0.15 We assumed dividend yield rate is 0.00% in Sharing Services. The volatility is based on the historical volatility of the Sharing Services’ common stock. Risk-free interest rates were obtained from U.S. Treasury rates for the applicable periods. Changes in the observable input values would likely cause material changes in the fair value of the Company’s Level 3 financial instruments. A significant increase (decrease) in this likelihood would result in a higher (lower) fair value measurement. The table below provides a summary of the changes in fair value, including net transfers in and/or out of all financial assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2021 and 2020: Total Balance at January 1, 2021 $ 66,978 Total losses (1,987 ) Balance at March 31, 2021 $ 64,991 Total Balance at January 1, 2020 $ 26,209 Total losses (12,599 ) Balance at March 31, 2020 $ 13,610 Vector Com Convertible Bond On February 26, 2021, the Company invested approximately $88,599 in the convertible bond of Vector Com Co., Ltd (“Vector Com”), a private company in South Korea. The interest rate is 2% per annum and maturity is two years. The conversion price is approximately $21.26, per common share of Vector Com. As of March 31, 2021, the Management estimated that the fair value of the note to be $88,599, the initial transaction price. Warrants On March 2, 2020, the Company received warrants to purchase shares of AMRE, a related party private startup company, in conjunction with the Company lending a $200,000 promissory note. For further details on this transaction, refer to Note 9 Related Party Transactions, Note Receivable from a Related Party Company. As of March 31, 2021 and December 31, 2020, AMRE was a private company. Based the management’s analysis, the fair value of the warrants was $0 as of March 31, 2021 and December 31, 2020. On July 17, 2020, the Company purchased 122,039,000 shares, approximately 9.99% ownership, and 122,039,000 warrants with an exercise price of $0.0001 per share, from APW, for an aggregated purchase price of $122,039. We value APW warrants under level 3 category through a Black-Scholes option pricing model and the fair value of the warrants from APW were $862,723 as of December 31, 2020 and $2,188,264 as of March 31, 2021. F- 28 The fair value of the APW warrants under level 3 category as of March 31, 2021 and July 17, 2020 was calculated using a Black-Scholes valuation model valued with the following weighted average assumptions: March 31, 2021 December 31, 2020 Stock Price $ 0.0084 $ 0.0021 Exercise price 0.001 0.001 Risk free interest rate 1.74 % 0.88 % Annualized volatility 232.10 % 178.86 % Year to maturity 9.32 9.58 13. COMMITMENTS AND CONTINGENCIES Lots Sales Agreement On November 23, 2015, SeD Maryland Development LLC completed the $15,700,000 acquisition of Ballenger Run, a 197-acre land sub-division development located in Frederick County, Maryland. Previously, on May 28, 2014, the RBG Family, LLC entered into a $15,000,000 assignable real estate sales contract with NVR, by which RBG Family, LLC would facilitate the sale of the 197 acres of Ballenger Run to NVR. On December 10, 2014, NVR assigned this contract to SeD Maryland Development, LLC through execution of an assignment and assumption agreement and entered into a series of lot purchase agreements by which NVR would purchase 443 subdivided residential lots from SeD Maryland Development, LLC. On December 31, 2018, SeD Maryland entered into the Third Amendment to the Lot Purchase Agreement for Ballenger Run with NVR. Pursuant to the Third Amendment, SeD Maryland will convert the 5.9 acre CCRC parcel to 36 lots (the 28 feet wide villa lot) and sell to NVR. Through the three months ended on March 31, 2021 and 2020, NVR purchased 27 lots and 27 lots, respectively. Through March 31, 2021 and December 31, 2020, NVR had purchased a total of 415 and 388 lots, respectively. Leases The Company leases offices in Maryland, Singapore, Magnolia, Texas, Hong Kong and South Korea through leased spaces aggregating approximately 15,811 square feet, under leases expiring on various dates from December 2020 to March 2024. The leases have rental rates ranging from $2,265 to $23,297 per month. Our total rent expense under these office leases was $140,271 and $85,558 in the three months ended March 31, 2021 and 2020, respectively. The following table outlines the details of lease terms: Office Location Lease Term as of December 31, 2020 Renewed Lease term in 2021 Singapore June 2020 to June 2021 Hong Kong October 2020 to October 2022 South Korea August 2020 to August 2022 Magnolia, Texas, USA November 2019 to April 2021 May 2021 to October 2021 Bethesda, Maryland, USA August 2015 to December 2020 January 2021 to March 2024 F- 29 The Company adopted ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) to recognize a right-of-use asset and a lease liability for all the leases with terms greater than twelve months. We elected the practical expedient to not recognize operating lease right-of-use assets and operating lease liabilities for lease agreements with terms less than 12 months. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide a readily determinable implicit rates, we estimate our incremental borrowing rates to discount the lease payments based on information available at lease commencement. Our incremental borrowings rates are 3.9% in 2021 and at a range from 0.5% to 4.5% per annum in 2020, which were used as the discount rates. The balances of operating lease right-of-use assets and operating lease liabilities as of March 31, 2021 were $722,507 and $736,561, respectively. The balances of operating lease right-of-use assets and operating lease liabilities as of December 31, 2020 were $574,754 and $574,754, respectively. The table below summarizes future payments due under these leases as of March 31, 2021. For the Years Ended December 31: 2021 $ 341,827 2022 292,830 2023 95,104 2024 24,430 Total Minimum Lease Payments 754,191 Less: Effect of Discounting (17,630 ) Present Value of Future Minimum Lease Payments 736,561 Less: Current Obligations under Leases (51,686 ) Long-term Lease Obligations 684,875 14. DIRECTORS AND EMPLOYEES’ BENEFITS Stock Option plans AEI The Company reserves 500,000 shares of common stock under the Incentive Compensation Plan for high-quality executives and other employees, officers, directors, consultants and other persons who provide services to the Company or its related entities. This plan is meant to enable such persons to acquire or increase a proprietary interest in the Company in order to strengthen the mutuality of interests between such persons and the Company’s shareholders, and providing such persons with performance incentives to expand their maximum efforts in the creation of shareholder value. As of March 31, 2021 and December 31, 2020, there have been no options granted. Alset International Stock Option plans On November 20, 2013, Alset International approved a Stock Option Plan (the “2013 Plan”). Employees, executive directors, and non-executive directors (including the independent directors) are eligible to participate in the 2013 Plan. F- 30 The following tables summarize stock option activity under the 2013 Plan for the three months ended March 31, 2021: Options for Remaining Contractual Aggregate Common Shares Exercise Price Term (Years) Intrinsic Value Outstanding as of January 1, 2020 1,061,333 $ 0.09 4.00 $ - Vested and exercisable at January 1, 2020 1,061,333 $ 0.09 4.00 $ - Granted - - Exercised - - Forfeited, cancelled, expired - - Outstanding as of December 31, 2020 1,061,333 $ 0.09 3.00 $ - Vested and exercisable at December 31, 2020 1,061,333 $ 0.09 3.00 $ - Granted - - Exercised - - Forfeited, cancelled, expired - - Outstanding as of March 31, 2021 1,061,333 $ 0.09 2.75 $ - Vested and exercisable at March 31, 2021 1,061,333 $ 0.09 2.75 $ - 15. SUBSEQUENT EVENTS Purchase of Shares of Value Exchange International, Inc. The Company has entered into a securities purchase agreement dated April 5, 2021 with Value Exchange International, Inc. (“Value Exchange International”) in connection with the purchase of 6,500,000 shares of Value Exchange International’s common stock for an aggregate subscription price of $650,000. The acquisition of 6,500,000 shares of Value Exchange International’s common stock was completed on April 12, 2021. Ownership of Alset International On April 8, 2021, the Company exercised its warrants to purchase 139,834,471 shares of Alset International at an exercise price of Singapore $0.04. On May 12, 2021, Chan Heng Fai exercised warrants to purchase 76,925,000 shares of Alset International at an exercise price of Singapore $0.048. On May 14 and 17, 2021, the Company exercised its warrants to purchase 943,531,983 shares of Alset International at an exercise price of Singapore $0.048. Total outstanding shares of Alset International were 2,931,951,400 after these issuances. The Company holds 2,094,516,748 shares of Alset International, approximately 71.4% ownership. Acquisition of HengFeng Finance Limited On October 15, 2020, the Company’s subsidiary, American Pacific Bancorp (“APB”), entered into an acquisition agreement to acquire 3,500,001 common shares of Hengfeng Finance Limited (“HFL”), representing 100% of the common shares of HFL, in consideration for 250,000 shares of APB’s Class A Common Stock. HFL is incorporated in Hong Kong with limited liability. This transaction closed on April 21, 2021. F- 31 Joint Venture with Novum On April 20, 2021 on of Company’s indirect subsidiaries, SeD Capital Pte. Ltd. (“SeD Capital”), entered into joint venture agreement with digital asset management firm Novum Alpha Pte Ltd (“Novum”). Pursuant to this agreement, SeD Capital will own 50% of the issued and paid-up capital in the joint venture company, Credas Capital Pte Ltd (“Credas”) with the remaining 50% shareholding stake held by Novum. Credas intends to develop and launch its maiden digital assets-based Exchange-Traded Product in the fourth quarter of 2021 on the SIX Swiss Exchange, Switzerland’s principal stock exchange and one of Europe’s largest stock exchanges. Distribution to Minority Shareholders On April 30, 2021, the Board of Managers of SeD Maryland Development LLC (the 83.55% owned subsidiary of the Company which owns the Company’s Ballenger Project) authorized the payment of distributions to its members in the amount of $3,000,000. Accordingly, the minority member of SeD Maryland Development LLC received a distribution in the amount of $493,500, with the remainder being distributed to a subsidiary of the Company, which is eliminated upon consolidation. Amendment to Authorized Shares and Designation of Preferred Shares On May 3, 2021, the holder of a majority of the issued and outstanding shares of common stock of the Company, by written consent, approved and adopted an amendment to our Third Amended and Restated Certificate of Incorporation (the “Amendment”) to increase the number of authorized shares of the Company’s common stock from Twenty Million (20,000,000) common shares to Two Hundred and Fifty Million (250,000,000) common shares and its preferred shares from Five Million (5,000,000) to Twenty Five Million (25,000,000). As of filing date, the amendment is still pending approval from State of Delaware. On May 3, 2021, the Company filed an amendment to its Articles of Incorporation which sets forth the rights and preferences of the Series A Convertible Preferred Stock. Pursuant to the Series A Designation, 6,380 shares of the Company’s preferred stock was designated Series A Preferred Stock. Holders of the Series A Preferred Stock shall be entitled to receive dividends equal, on an as-if-converted basis, to and in the same form as dividends actually paid on shares of the Company’s common stock par value $0.001 per share (“Common Stock”) when, as and if paid on shares of Common Stock. Each holder of outstanding Series A Preferred Stock is entitled to vote equal to the number of whole shares of Common Stock into which each share of the Series A Preferred Stock is convertible. Holders of Series A Preferred Stock are entitled, upon liquidation of the Company, to receive the same amount that a holder of Series A Preferred Stock would receive if the Series A Preferred Stock were fully converted into Common Stock. On May 12, 2021 the Company filed a Certificate of Designation which sets forth the rights and preferences of the Series B Preferred Stock. Pursuant to the Series B Designation, 2,132 shares of the Company’s preferred stock was designated Series B Preferred Stock. Holders of the Series B Preferred Stock shall be entitled to receive dividends equal, on an as-if-converted basis, to and in the same form as dividends actually paid on shares of the Company’s common stock par value $0.001 per share (“Common Stock”) when, as and if paid on shares of Common Stock. Each holder of outstanding Series B Preferred Stock is entitled to vote equal to the number of whole shares of Common Stock into which each share of the Series B Preferred Stock is convertible. Holders of Series B Preferred Stock are entitled, upon liquidation of the Company, to receive the same amount that a holder of Series B Preferred Stock would receive if the Series B Preferred Stock were fully converted into Common Stock. Loan and Exchange Agreement with the CEO, Chan Heng Fai On May 3, 2021, the Company entered into a Loan and Exchange Agreement with its Chief Executive Officer, Chan Heng Fai pursuant to which Chan Heng Fai loaned the Company his shares of Common Stock of the Company by exchanging 6,380,000 shares of common stock which he owned for an aggregate of 6,380 shares of the Company’s newly designated Series A Convertible Preferred Stock. On May 12, 2021, Company entered into an Exchange Agreement with Chan Heng Fai, effective May 13, 2021, pursuant to which he exchanged $13,000,000 in principal amount under a $28,363,966 convertible promissory note (the “Note”) in exchange for 2,132 shares of the Company’s newly designated Series B Preferred Stock. F- 32 Public Offering On May 10, 2021, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp., as the sole book-running manager and representative of the underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of (i) 4,700,637 common units (the “Common Units”), at a price to the public of $5.07 per Common Unit, with each Common Unit consisting of (a) one share of common stock, par value $0.001 per share (the “Common Stock”), (b) one Series A warrant (the “Series A Warrant” and collectively, the “Series A Warrants”) to purchase one share of Common Stock with an initial exercise price of $5.07 per whole share, exercisable until the fifth anniversary of the issuance date, and (c) one Series B warrant (the “Series B Warrant” and collectively, the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase one-half share of Common Stock with an initial exercise price of $6.59 per whole share, exercisable until the fifth anniversary of the issuance date and (ii) 1,611,000 pre-funded units (the “Pre-funded Units”), at a price to the public of $5.06 per Pre-funded Unit, with each Pre-funded Unit consisting of (a) one pre-funded warrant (the “Pre-funded Warrant” and collectively, the “Pre-funded Warrants”) to purchase one share of Common Stock, (b) one Series A Warrant and (c) one Series B Warrant. The shares of Common Stock, the Pre-funded Warrants, and the Warrants were offered together, but the securities contained in the Common Units and the Pre-funded Units were issued separately. The Company also granted the Underwriters a 45-day over-allotment option to purchase up to 808,363 additional shares of Common Stock and/or up to 808,363 additional Series A Warrants to purchase 808,363 shares of Common Stock, and/or up to 808,363 additional Series B warrants to purchase 404,181 shares of Common Stock. The Offering, including the partial exercise of the Underwriters’ over-allotment option to purchase 808,363 Series A Warrants and 808,363 Series B Warrants, closed on May 13, 2021. The Company paid the Underwriters an underwriting discount equal to 6.5% of the gross proceeds of the Offering and a non-accountable expense fee equal to 1.25% of the gross proceeds of the Offering. The Company also reimbursed the Underwriters for certain of their expenses, including “roadshow”, diligence, and reasonable legal fees and disbursements, in an amount of $150,000 in the aggregate. The Company has also agreed that it will not issue or announce the issuance or proposed issuance of any Common Stock or Common Stock equivalents for a period of 120 days following the closing date, other than certain exempt issuances. The net proceeds to the Company from the Offering were approximately $29.2 million, excluding the proceeds, if any, from the exercise of the Warrants and the Pre-funded Warrants sold in the Offering, and after deducting underwriting discounts and commissions and the payment of other estimated offering expenses associated with the Offering that are payable by the Company. Note Payable Related Party On May 14, 2021, Alset EHome International Inc., a Delaware corporation (the “Company”), borrowed S$7,395,472 Singapore Dollars (equal to approximately $5,557,371 U.S. Dollars) from the Company’s Chairman, Chief Executive Officer and major stockholder, Chan Heng Fai. The unpaid principal amount of the Loan shall be due and payable on May 14, 2022 and the Loan shall have no interest. F- 33 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Forward-Looking Statements This Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may”, “will”, “expect”, “believe”, “anticipate”, “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include by are not limited to economic conditions generally and in the industries in which we may participate, competition within our chosen industry, including competition from much larger competitors, technological advances and failure to successfully develop business relationships. Business Overview Alset EHome International Inc. is a fast-growing diversified holding company principally engaged in property development, digital transformation technology and biohealth activities with operations is United States, Singapore, Hong Kong and Australia. Our growth strategy is both, to pursue opportunities that we can leverage on our global network using our capital resources and to accelerate the expansion of our organic businesses. We manage our three principal businesses primarily through our 71.4% ( as of the filing date) owned subsidiary, Alset International Limited, a public company traded on the Singapore Stock Exchange. Financial Impact of the COVID-19 Pandemic Real Estate Projects The extent to which the COVID-19 pandemic may impact our business will depend on future developments, which are highly uncertain and cannot be predicted. The COVID-19 pandemic’s far-reaching impact on the global economy could negatively affect various aspects of our business, including demand for real estate. From March through December 2020, we continued to sell lots at our Ballenger Run project (in Maryland) for the construction of town homes to NVR. Sales of such homes to NVR were at the same level in the first three months of 2021 as in the first three months of 2020. In first quarter of 2021 and 2020 we sold 27 lots to NVR. Such town homes are often a first home that generally did not require buyers to sell an existing home. We believe low interest rates have encouraged home sales. Many buyers opted to see home models at the project virtually. This technology allowed them to ask questions to sales staff and see the town homes. Home closings were able to occur electronically. We have received strong indications that buyers and renters across the country are expressing interest in moving from more densely populated urban areas to the suburbs. We believe that our Ballenger Run project is well suited and positioned to accommodate those buyers. Our latest phase for sale at Ballenger Run, involving single-family homes, has seen a high number of interested potential buyers signing up for additional information and updates on home availability. The COVID-19 pandemic could impact the ability of our staff and contractors to continue to work, and our ability to conduct our operations in a prompt and efficient manner. To date, we experienced a slowdown in the construction of a clubhouse at the Ballenger Run project, which was completed behind schedule. We believe this delay was caused in part by policies requiring lower numbers of contractors working in indoor spaces. The COVID-19 pandemic may adversely impact the timeliness of local government in granting required approvals. Accordingly, the COVID-19 pandemic may cause the completion of important stages in our real estate projects to be delayed. 2 Impact on Staff Most of our U.S. staff works out of our Bethesda, Maryland office. At our office in Texas, we received a 50% rent abatement for the month of May 2020. Our U.S. staff has shifted to mostly working from home since March 2020, but this has had a minimal impact on our operations to date. Our staff in Singapore and Hong Kong has been able to work from home when needed with minimal impact on our operations, however our staff’s ability to travel between our Hong Kong and Singapore offices has been significantly limited, and our staff’s travel between the U.S. and non-U.S. offices has been suspended since March 2020. The COVID-19 pandemic has also impacted the frequency with which our management would otherwise travel to the Black Oaks project; however, we have a contractor in Texas providing supervision of the project. Management continues to regularly supervise the Ballenger Run project. Limitations on the mobility of our management and staff may slow down our ability to enter into new transactions and expand existing projects. We have not reduced our staff in connection with the COVID-19 pandemic. To date, we did not have to expend significant resources related to employee health and safety matters related to the COVID-19 pandemic. We have a small staff, however, and the inability of any significant number of our staff to work due to illness or the illness of a family member could adversely impact our operations. Matters that May or Are Currently Affecting Our Business In addition to the matters described above, the primary challenges and trends that could affect or are affecting our financial results include: ● Our ability to improve our revenue through cross-selling and revenue-sharing arrangements among our diverse group of companies; ● Our ability to identify complementary businesses for acquisition, obtain additional financing for these acquisitions, if and when needed, and profitably integrate them into our existing operation; ● Our ability to attract competent, skilled technical and sales personnel for each of our businesses at acceptable compensation levels to manage our overhead; and ● Our ability to control our operating expenses as we expand each of our businesses and product and service offerings. Results of Operations Summary of Statements of Operations for the Three Months Ended March 31, 2021 and 2020 Three Months Ended March 31, 2021 2020 Revenue $ 5,606,914 $ 2,965,171 Operating Expenses 6,010,359 3,387,562 Other Income (Expense) (8,949,966 ) 2,677,956 Net (Loss) Income $ (9,804,748 ) $ 2,255,565 3 Revenue The following tables sets forth period-over-period changes in revenue for each of our reporting segments: Three Months Ended March 31, Change 2021 2020 Dollars Percentage Property development $ 3,894,131 $ 2,954,389 $ 939,742 32 % Biohealth 1,712,783 10,782 1,702,001 15,786 % Digital transformation technology - - - - Other - - - - Total revenue $ 5,606,914 $ 2,965,171 $ 2,641,743 89 % Revenue was $5,606,914 and $2,965,171 for the three months ended March 31, 2021 and 2020, respectively. An increase in property sales from the Ballenger Project and direct sales from HWH World in the first quarter of 2021 contributed to higher revenue in that period. For our Ballenger Project, builders are required to purchase a minimum number of lots based on their applicable sale agreements. We collect revenue only from the sale of lots to builders. We are not involved in the construction of homes at the present time. Income from the sale of Front Foot Benefits (“FFBs”), assessed on Ballenger Run project lots, increased from $40,322 in the three months ended March 31, 2020 to $107,071 in the three months ended March 31, 2021. The increase is a mixed result of the increased sale of properties to homebuyers in the first quarter of 2021 and sale of FFBs of a higher value. Revenues from our biohealth segment in the first quarter of 2020 come from the direct sales by iGalen Inc. (formerly known as iGalen USA, LLC), which is 100% owned by iGalen International Inc., Alset International’s 53%-owned subsidiary. On December 30, 2020 Alset International’s ownership of iGalen International was sold to one of the directors of iGalen International. During the three months ended March 31, 2020, the revenue from iGalen Inc. was $10,782. In recent years, the Company expanded its biohealth segment to Korean market through one of the subsidiaries of Health Wealth Happiness Pte. Ltd., HWH World Inc (“HWH World”). HWH World, similarly to iGalen Inc., operates based on a direct sale model of health supplements. HWH World recognized $1,702,001 and $0 in revenue in three months ended March 31, 2021 and 2020, respectively. Operating Expenses The following tables sets forth period-over-period changes in cost of sales for each of our reporting segments: Three Months Ended March 31, Change 2021 2020 Dollars Percentage Property development $ 3,614,832 $ 2,380,820 $ 1,234,012 52 % Biohealth 83,022 2,883 80,139 2,780 % Digital transformation technology - - - - Other - - - - Total Cost of Sales $ 3,697,854 $ 2,383,703 $ 1,314,151 55 % Cost of sales increased from $2,380,820 in the three months ended March 31, 2020 to $3,614,832 in the three months ended March 31, 2021, as a result of the increase in sales in the Ballenger Run project. Capitalized construction expenses, finance costs and land costs are allocated to sales. We anticipate the total cost of sales to increase as revenue increases. 4 The gross margin increased from $581,468 to $1,909,060 in the three months ended March 31, 2020 and 2021, respectively. The increase of gross margin was caused by the increase of gross margin of HWH World, mostly due to the increase in the sales. The following tables sets forth period-over-period changes in operating expenses for each of our reporting segments. Three Months Ended March 31, Change 2021 2020 Dollars Percentage Property development $ 359,489 $ 277,056 $ 82,433 30 % Biohealth 846,480 132,791 713,689 537 % Digital transformation technology 30,128 18,228 11,900 65 % Other 1,076,408 575,784 500,624 87 % Total operating expenses $ 2,312,505 $ 1,003,859 $ 1,308,646 130 % The increase of operating expenses of property development in 2021 compared with 2020 was mostly caused by the increase of sales related expenses. Increase in expenses in our biohealth business is caused by the increased commission payments to our distributors, which is connected to increased sales. Other Income (Expense) In the three months ended March 31, 2021, the Company had other expense of $8,949,966 compared to other income of $2,677,956 in the three months ended March 31, 2020. The change in unrealized gain (loss) on securities investment and on foreign exchange transactions are the primary reasons for the volatility in these two periods. Unrealized loss on securities investment was $9,535,009 in three months ended March 31, 2021, comparing to $458,422 gain in the three months ended March 31, 2020. Foreign exchange transaction gain was $1,462,697 in the three months ended March 31, 2021, compared to $2,260,482 gain in the three months ended March 31, 2020. Net Income (Loss) In the three months ended March 31, 2021 the Company had net loss of $9,353,411 compared to net income of $2,255,565 in the three months ended March 31, 2020. Liquidity and Capital Resources Our real estate assets under development have decreased to $20,265,713 as of March 31, 2021 from $20,505,591 as of December 31, 2020. This decrease primarily reflects an increase in sales of lots and a higher increase in costs of sales than in the capitalized costs related to the construction in progress. On March 31, 2021, we purchased 10 homes, which will be used in Company’s rental business. Our cash has decreased from $24,465,923 as of December 31, 2020 to $20,368,692 as of March 31, 2021. Our liabilities increased from $9,533,735 at December 31, 2020 to $23,252,927 at March 31, 2021. Our total assets have increased to $108,797,989 as of March 31, 2021 from $107,211,921 as of December 31, 2020 mainly due to the increase in cash and investments in securities. Summary of Cash Flows for the Three Months Ended March 31, 2021 and 2020 Three Months Ended March 31, 2021 2020 Net cash used in operating activities $ (3,304,857 ) $ (182,597 ) Net cash provided by investing activities $ 2,352,536 $ 101,963 Net cash provided by (used in) financing activities $ (956,264 ) $ 2,030,592 Cash Flows from Operating Activities Net cash used in operating activities was $3,304,857 in the first three months of 2021, as compared to net cash used in operating activities of $182,597 in the same period of 2020. The higher prepayments and purchase of trading securities for investment purposes explained the increased cash flow used in operating activities in the first three months of 2021. 5 Cash Flows from Investing Activities Net cash provided by investing activities was $2,352,536 in the first three months of 2021, as compared to net cash provided by investing activities of $101,963 in the same period of 2020. In the three months ended March 31, 2021 we invested $108,208 in securities and received approximately $2.5 million from the sale of Vivacitas Oncology to a related party. In the three months ended March 31, 2020, we received $303,349 from the liquidation of Global Opportunity Fund. We also invested $200,000 in a promissory note of a related party. Cash Flows from Financing Activities Net cash used in financing activities was $956,264 in the three months ended March 31, 2021, comparing to net cash provided of $2,030,592 the three months ended March 31, 2020. The increase in cash used in financing activities is primarily caused by the increase in cash used to repay related party note payable. During the three months ended March 31, 2021, we received cash proceeds of $7,484 from the exercise of subsidiary warrants, $250,000 from the sale of our GigWorld shares to individual investors and $68,502 from a loan. The Company also distributed $82,250 to one minority interest investor and repaid $1,200,000 of promissory note held by related parties. During the three months ended March 31, 2020, we received cash proceeds of $2,210,491 from the issuance of stock through a subsidiary’s private placement, distributed $197,400 to one minority interest investor and borrowed $17,501 from related party loan. Off-Balance Sheet Arrangements We do not have any off-balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, results of operations, liquidity or capital expenditures. Impact of Inflation We believe that inflation has not had a material impact on our results of operations for the three months ended March 31, 2021 or the year ended December 31, 2020. We cannot assure you that future inflation will not have an adverse impact on our operating results and financial condition. Impact of Foreign Exchange Rates The effect of foreign exchange rate changes on the intercompany loans (under ASC 830), which mostly consist of loans from Singapore to the United States and which were approximately $27.1 million and $24.8 million on March 31, 2021 and December 31, 2020, respectively, are the reason for the significant fluctuation of foreign currency transaction Gain or Loss on the Consolidated Statements of Operations and Other Comprehensive Income. Because the intercompany loan balances between Singapore and United States will remain at approximately $25 million over the next year, we expect this fluctuation of foreign exchange rates to still significantly impact the results of operations in 2021, especially given that the foreign exchange rate may and is expected to be volatile. If the amount of intercompany loan is lowered in the future, the effect will also be reduced. However, at this moment, we do not expect to repay the intercompany loans in the short term. Emerging Growth Company Status We are an “emerging growth company,” as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies.” Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of these exemptions until we are no longer an emerging growth company or until we affirmatively and irrevocably opt out of this exemption. 6 Seasonality The real estate business is subject to seasonal shifts in costs as certain work is more likely to be performed at certain times of year. This may impact the expenses of Alset EHome Inc. from time to time. In addition, should we commence building homes, we are likely to experience periodic spikes in sales as we commence the sales process at a particular location. Item 3. Quantitative and Qualitative Disclosures about Market Risk As a “smaller reporting company” as defined by Item 10(f)(1) of Regulation S-K, the Company is not required to provide the information required by this Item. Item 4. Controls and Procedures (a) Evaluation of Disclosure Controls and Procedures As of the end of the period covered by this report, an evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officers, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officers, concluded that our disclosure controls and procedures are not effective as of March 31, 2021 to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officers, as appropriate to allow timely decisions regarding required disclosure. (b) Changes in the Company’s Internal Controls Over Financial Reporting There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) that occurred during the quarterly period ended March 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Part II. Other Information Item 1. Legal Proceeding Not Applicable for the period covered by this report. Item 1A. Risk Factors Not applicable to smaller reporting companies. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds The Company has not sold any unregistered shares during the period covered by this Report or through May 24, 2021; however, on January 19, 2021, the Company issued 10,000 shares of its common stock for public relations services. Such securities were not registered under the Securities Act of 1933 and were issued pursuant to the exemption under Section 4(2) of the Securities Act. On May 3, 2021, the Company entered into a Loan and Exchange Agreement with its Chairman and Chief Executive Officer, Chan Heng Fai pursuant to which Chan Heng Fai loaned the Company his shares of Common Stock of the Company by exchanging 6,380,000 shares of common stock which he owned for an aggregate of 6,380 shares of the Company’s newly designated Series A Convertible Preferred Stock. Such securities were not registered under the Securities Act of 1933 and were issued pursuant to the exemption under Section 3(a)(9) of the Securities Act. On May 12, 2021, Company entered into an Exchange Agreement with our Chairman and Chief Executive Officer Chan Heng Fai, effective May 13, 2021, pursuant to which Chan Heng Fai exchanged $13,000,000 in principal amount under a $28,363,966 convertible promissory note in exchange for 2,132 shares of the Company’s newly designated Series B Preferred Stock. Such securities were not registered under the Securities Act of 1933 and were issued pursuant to the exemption under Section 3(a)(9) of the Securities Act. On May 10, 2021, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp., as the sole book-running manager and representative of the underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of (i) 4,700,637 common units (the “Common Units”), at a price to the public of $5.07 per Common Unit, with each Common Unit consisting of (a) one share of common stock, par value $0.001 per share (the “Common Stock”), (b) one Series A warrant (the “Series A Warrant” and collectively, the “Series A Warrants”) to purchase one share of Common Stock with an initial exercise price of $5.07 per whole share, exercisable until the fifth anniversary of the issuance date, and (c) one Series B warrant (the “Series B Warrant” and collectively, the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase one-half share of Common Stock with an initial exercise price of $6.59 per whole share, exercisable until the fifth anniversary of the issuance date and (ii) 1,611,000 pre-funded units (the “Pre-funded Units”), at a price to the public of $5.06 per Pre-funded Unit, with each Pre-funded Unit consisting of (a) one pre-funded warrant (the “Pre-funded Warrant” and collectively, the “Pre-funded Warrants”) to purchase one share of Common Stock, (b) one Series A Warrant and (c) one Series B Warrant. The shares of Common Stock, the Pre-funded Warrants, and the Warrants were offered together, but the securities contained in the Common Units and the Pre-funded Units were issued separately. The Offering was made pursuant to the Company’s registration statement on Form S-1 (File Number 333-255757), which was declared effective on May 10, 2021. The Company also granted the Underwriters a 45-day over-allotment option to purchase up to 808,363 additional shares of Common Stock and/or up to 808,363 additional Series A Warrants to purchase 808,363 shares of Common Stock, and/or up to 808,363 additional Series B warrants to purchase 404,181 shares of Common Stock. The Offering, including the partial exercise of the Underwriters’ over-allotment option to purchase 808,363 Series A Warrants and 808,363 Series B Warrants, closed on May 13, 2021. The net proceeds to the Company from the Offering was approximately $29.2 million, excluding the proceeds, if any, from the exercise of the Warrants and the Pre-funded Warrants sold in the Offering, and after deducting underwriting discounts and commissions and the payment of other estimated offering expenses associated with the Offering that are payable by the Company. On May 17, 2021, the Company paid S$37,894,063.20 Singapore Dollars (equal to approximately $28,475,719 U.S. Dollars) received from the Offering to exercise warrants to purchase 789,459,650 shares of Alset International Limited at an exercise price of S$.048 Singapore Dollars (equal to approximately $.036 U.S. Dollars) per share. The proceeds have been received by Alset International Limited. Item 3. Defaults Upon Senior Securities None. Item 4. Mine Safety Disclosures Not Applicable. 7 Item 5. Other Information None. Item 6. Exhibits The following documents are filed as a part of this report: 1.1 Underwriting Agreement, dated as of May 10, 2021, by and between Alset EHome International Inc. and Aegis Capital Corp., as representative of the underwriters named therein, incorporated herein by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 14, 2021. 3.1 Certificate of Merger, incorporated herein by reference to Exhibit 3.5 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 11, 2021. 3.2 Certificate of Designation of the Company’s Series A Convertible Preferred Stock, incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 4, 2021. 3.3 Certificate of Designation of the Company’s Series B Convertible Preferred Stock, incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 12, 2021. 4.1 Pre-funded Warrant Agent Agreement (including the terms of the Pre-funded Warrant), incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 14, 2021. 4.2 Series A Warrant Agent Agreement (including the terms of the Series A Warrant), incorporated herein by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 14, 2021. 4.3 Series B Warrant Agent Agreement (including the terms of the Series B Warrant), incorporated herein by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 14, 2021. 10.1 Binding Term Sheet on Share Exchange Transaction Among HF Enterprises Inc. and Mr. Chan Heng Fai Ambrose, dated January 4, 2021, incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 12, 2021. 10.2 Term Sheet by and among Document Security Systems, Inc., Alset International Limited, Health Wealth Happiness Pte. Ltd., and HWH World Inc. dated January 6, 2021, incorporated herein by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 7, 2021. 10.3 Executive Employment Agreement, by and between Alset EHome International Inc., Hengfai Business Development Pte Ltd. and Chan Heng Fai, dated as of February 8, 2021, incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 12, 2021. 10.4 Securities Purchase Agreement By and Among Alset EHome International Inc., Chan Heng Fai Ambrose, True Partners International Limited, LiquidValue Development Pte Ltd. and American Pacific Bancorp, Inc. dated March 12, 2021, incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2021. 10.5 2% Conditional Convertible Promissory Note dated March 12, 2021, in the principal amount of $28,363,966.42, incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2021. 10.6 2% Conditional Convertible Promissory Note dated March 12, 2021, in the principal amount of $173,394.87, incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2021. 10.7 2% Conditional Convertible Promissory Note dated March 12, 2021, in the principal amount of $6,729,629.29, incorporated herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2021. 8 10.8 2% Conditional Convertible Promissory Note dated March 12, 2021, in the principal amount of $28,653,138.00, incorporated herein by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2021. 10.9 Loan and Exchange Agreement By and Between the Company and Chan Heng Fai, incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 4, 2021. 10.10 Exchange Agreement By and Between the Company and Chan Heng Fai, incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 12, 2021. 10.11 Promissory Note, incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 20, 2021. 31.1* Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2a * Certification of Co-Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2b * Certification of Co-Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 ** Certifications of the Chief Executive Officer and Chief Financial Officers pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS XBRL Instance Document 101.SCH XBRL Taxonomy Extension Schema Document 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF XBRL Taxonomy Extension Definition Linkbase Document 101.LAB XBRL Taxonomy Extension Label Linkbase Document 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document * Filed herewith. ** Furnished herewith. 9 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ALSET EHOME INTERNATIONAL INC. May 24, 2021 By: /s/ Chan Heng Fai Chan Heng Fai Chairman of the Board and Chief Executive Officer (Principal Executive Officer) May 24, 2021 By: /s/ Rongguo Wei Rongguo Wei Co-Chief Financial Officer (Principal Financial and Accounting Officer) May 24, 2021 By: /s/ Lui Wai Leung Alan Lui Wai Leung Alan Co-Chief Financial Officer (Principal Financial and Accounting Officer) 10